

11. PUBLICATIONS CB EAP (ORCID NUMBER: 0000-0002-5439-0230)

Scopus (October 2023):

H-index: 58

Sum of the times cited: >9500

Original papers published in peer reviewed journals

- 1) C-J Ruan, I Olmos, C Ricciardi, G Schoretsanitis, PD Vincenth, AE Anil Yağcıoğlu, **CB Eap**, T Baptista, SR Clark, E Fernandez-Egea, SH Kim, H-Y Lane, J Leung, O Maroñas Amigo, M Motuca, S Every-Palmer, RM Procyshyn, CG Rohde, S Suhas, PFJ Schulte, E Spina, H Takeuchi, H Verdoux, CU Correll, C De Las Cuevas, J de Leon. Exploring low clozapine C/D ratios, inverted clozapine-norclozapine ratios and undetectable concentrations as measures of non-adherence in clozapine patients. A literature review and a case series of 17 patients from 3 studies. *Schizophrenia Research*; <https://doi.org/10.1016/j.schres.2023.07.002>
- 2) J Sjaarda*, Aurélie Delacrétaz*, C Dubath, N Laaboub, M Piras, C Grosu, F Vandenberghe, S Crettol Wavre, N Ansermot, F Gamma, K Jessica Plessen, A von Gunten, P Conus, Z Kutalik*, **CB Eap***. Identification of four novel loci associated with psychotropic drug-induced weight gain in a Swiss psychiatric longitudinal study: a GWAS analysis. *Molecular Psychiatry*; <https://doi.org/10.1038/s41380-023-02082-3>
*First or last joint authorship
- 3) C Grosu, W Hatoum, M Piras, N Laaboub, S Ranjbar, F Gamma, K J. Plessen, A von Gunten, M Preisig, P Conus, **CB Eap**. Associations of valproate doses with weight gain in adult psychiatric patients: a 1-year prospective cohort study. *J Clin Psy* (in press).
- 4) G Schoretsanitis, A Elif Anil Yağcıoğlu, CJ Ruan, **CB Eap**, E Molden, T Baptista, SR Clark, E Fernandez-Egea, SH Kim; H-Y Lane, J Leung, O Maroñas Amigo, M Motuca, I Olmos, S Every-Palmer, RM Procyshyn, C G Rohde, S Satish, PFJ Schulte, E Spina, H Takeuchi, H Verdoux, CU Correll; Jose de Leon. Clozapine ultrarapid metabolism during weak induction probably exists but requires careful diagnosis. A literature review, five new cases and a proposed definition. *Schizophrenia Research* (in press)
- 5) A Monfort, E Cardoso, **CB Eap**, C Fisher, M Bickle Graz, M Morisod Harari, E Weisskopf, P Gandia, Karel Allegaert, H Nordeng, J-M Hascoët, O Claris, M Epiney, C Csajka, M Guidi, E Ferreira, A Panchaud and collaborators of the SSRI Breast Milk study. Infant exposure to Fluvoxamine through placenta and human milk: A case series. *Frontiers in Psychiatry* (in press)
- 6) M Piras, J Chahma, S R, N Laaboub, C Grosu, K Jessica Plessen, A von Gunten, P Conus, **CB Eap**. Is clozapine induced weight gain dose dependent? Results from a prospective cohort study. *Schizophrenia Bulletin*; <https://doi.org/10.1093/schbul/sbad009>
- 7) N Kuzo, E Haen, DM Ho, H Takeuchi, M Piras, **CB Eap**, R de Filippis, J Kane, M Paulzen, G Schoretsanitis. Clozapine Once- Versus Multiple-Daily Dosing: a two-center cross-sectional study, systematic review and meta-analysis. *European Archives of Psychiatry and Clinical Neuroscience*. (2022). <https://doi.org/10.1007/s00406-022-01542-1>
- 8) Piras, S Ranjbar, N Laaboub, C Grosu, F Gamma, K Jessica Plessen, A von Gunten, P Conus, **CB Eap**. Evolutions of metabolic parameters following switches of psychotropic drugs: a longitudinal cohort study. *Schizophrenia Bulletin* <https://doi.org/10.1093/schbul/sbac133> (2022)
- 9) P Garin, L Favre, N Vionnet, J Frantz, CB Eap, F Vandenberghe. Influence of bariatric surgery on plasma levels of antidepressants: analysis of a therapeutic drug monitoring database. *Obesity Surgery* 2023 DOI 10.1007/s11695-023-06526-1
- 10) N Laaboub, C Dubath, S Ranjbar, G Sibailly, C Grosu, M Piras, D Délessert, H Richard-Lepouriel, N Ansermot, S Crettol, F Vandenberghe, C Grandjean, A Delacrétaz, F Gamma, K Jessica Plessen, A von Gunten, P Conus, **CB Eap**. Insomnia disorders are associated with increased cardiometabolic disturbances and death risks from cardiovascular diseases in psychiatric patients treated with weight-gain-inducing psychotropic drugs: results from a Swiss cohort. *BMC Psychiatry* (2022) 10.1186/s12888-022-03983-3
- 11) BI Perry*, F Vandenberghe*, N Garrido-Torres*, EF Osimo, M Piras, J Vazquez-Bourgon, R Upthegrove, C Grosu, V Ortiz-Garcia De La Foz, PB Jones, N Laaboub, MI Ruiz-Veguilla, J Stoch, C Dubath, M Canal-Rivero, P Mallikarjun, A Reymond-Delacrétaz, N Ansermot, E Fernandez-Egea, S Crettol, F Gamma, K Von Plessen, P Conus, G M Khandaker, GK Murray*, CB. Eap*, B Crespo-Facorro*. The Psychosis Metabolic Risk Calculator (PsyMetRiC) for Young People with Psychosis: International External Validation and Site-Specific Recalibration in Two Independent European Samples. *The Lancet Regional Health* August 2022; <https://doi.org/10.1016/j.lanpe.2022.100493>
*joint first or last authors

- 12) Laaboub N, Gholam M, Sibailly G, Sjaarda J, Delacrétaz A, Dubath C, Grosu C, Piras M, Ansermot N, Crettol S, Vandenberghe F, Grandjean C, Gamma F, Bochud M, von Gunten A, Plessen KJ, Conus P, **Eap CB**. Associations between high plasma methylxanthine levels, sleep disorders and polygenic risk scores of caffeine consumption or sleep duration in a Swiss psychiatric cohort. *Frontiers in Psychiatry* 2021;12:756403.
- 13) Pardiñas AF, Smart SE, Willcocks I-R, Holmans PA, Dennison CA, Lynham AJ, Legge SE, Kassoumeri L, Ajnakina O, Alameda L, Barnes TRE, Baune BT, Berardi D, Bigdeli TB, Bonora E, Cairns MJ, Camporesi S, Cleusix M, Conus P, Corvin A, Crespo-Facorro B, D'Andrea G, Demjaha A, Do KQ, Doody G, **Eap CB**, Fanous AH, Ferchiou A, Di Forti M, Frank J, Guidi L, Homman L, Jenni R, Joyce EM, Kelly B, Khadimallah I, Lastrina O, McQuillin A, Melle I, Mortensen PB, Mowry BJ, Muratori R, Noyan H, O'Neill FA, Pato CN, Pignon B, Periyasamy S, Restellini R, Richard J-R, Rietschel M, Rujescu D, Schürhoff F, Simonsen C, Španiel F, St Clair D, Szöke A, Tarricone I, Tooney P, Tortelli A, Üçok A, Vázquez-Bourgon J, Wu JQ, Andreassen OA, Kowalec K, Sullivan PF, Murray RM, Owen MJ, MacCabe JH, O'Donovan MC, Walters JTR, For the Schizophrenia Working Group of the Psychiatric Genomics Consortium and the Schizophrenia Treatment Resistance and Therapeutic Advances (STRATA) Consortium. Interaction testing and polygenic risk scoring to estimate the association of common genetic variants with treatment resistance in schizophrenia. *JAMA Psychiatry* 2022;79(3):260-269.
- 14) SE Smart, D Agbedjro , AF Pardiñas, O Ajnakina, L Alameda, OA Andreassen, TRE Barnes, D Berard, S Camporesi, M Cleusix, P Conus, B Crespo-Facorro, G D'Andrea, A Demjaha, M Di Fort, K Do, G Doody, **CB Eap**, A Ferchiou, L Guidi, L Homman, R Jenni, E Joyce, L Kassoumeri, O Lastrina, I Melle, C Morgan, FA O'Neill, B Pignon, R Restellini, JR Richard, C Simonsen, F Španiel, A Szöke, I Tarricone, A Tortelli, A Üçok, J Vázquez-Bourgon, RM Murray, JTR Walter , D Stah, JH MacCabe. Clinical Predictors of Antipsychotic Treatment Resistance: Development and internal validation of a prognostic prediction model by the STRATA-G Consortium. *Schizophrenia Research* (in press).
- 15) Grosu C, Trofimova, O, Gholam M, Strippoli M-P, Kherif F, Lutti A, Preisig M, Draganski B*, **Eap CB***. CYP2C19 expression modulates affective functioning and brain anatomy in a large-scale population-based study. *equal contribution. *Translational Psychiatry* (2022) 12:316 ; <https://doi.org/10.1038/s41398-022-02091-w>
- 16) Montavon F *, Vandenberghe F *, **Eap CB**. Use of pharmacological treatment for posttraumatic stress disorder: analysis of a psychiatric population in Switzerland. Submitted. * Joint first authorship. *L'encéphale* <https://www.sciencedirect.com/science/article/pii/S0013700622001245?via%3Dihub>
- 17) Schoretsanitis G, Dubath C, Grosu C, Piras M, Laaboub N, Ranjbar S, Ansermot N, Crettol S, Vandenberghe F, Gamma F, von Gunten A, Plessen KJ, Seifritz E, Conus P, **CB Eap**, Olanzapine-associated dose-dependent alterations for weight and metabolic parameters in a prospective cohort. *Basic Clin Pharmacol Toxicol* 2022;130(4):531-541
- 18) Golay P, Calderoni M, **Eap CB**, Conus P. French validation of the M-Back questionnaire: a tool to assess knowledge about metabolic syndrome among clinicians in psychiatry. *Swiss Archives of Neurology, Psychiatry and Psychotherapy* <https://sanp.ch/article/doi/sanp.2021.03224>
- 19) Lenski M, Sidibé J, Gholam M, Hennart B, Dubath C, Augsburger M, von Gunten A, Conus P, Allorge D, Thomas A*, **Eap CB***. Metabolomic alteration induced by psychotropic drugs: short term metabolite profile as a predictor of weight gain evolution. *Clinical and Translational Science* 2021Nov;14(6):2544-2555 * Equal contribution
- 20) Smogur M, Onesanu A, Plessen KJ, **Eap CB**, Ansermot N. Psychotropic Drug Prescription in Children and Adolescents: Approved Medications in European Countries and the United States. *J Child & Adolesc Psychopharmacol* (in press)
- 21) Dubath C, Piras M, Gholam M, Laaboub N, Grosu C, Sentissi O, Gamma F, Solida A, von Gunten A, Conus P, **Eap CB**. Effect of quetiapine, from low to high dose, on weight gain and metabolic traits: results from a prospective cohort study. *Pharmacopsychiatry* 54:279-86, 2021
- 22) Buso G, Favre L, Vionnet Fuasset N, Gomez Rodriguez E, Hans D, Puder J, Dubath C, **Eap CB**, Raffoul W, Collet T-H, Mazzolai L. Body composition assessment by dual-energy X-ray absorptiometry: a useful tool to diagnose lipoedema. *Obesity Facts* (in press)
- 23) Petrovic D, Pruijm M, Ponte B, Dhayat N, Ackermann D, Ehret G, Ansermot N, Vogt B, Martin P-Y, Stringhini S, Estoppey-Younès S, Thijs L, Zhang Z, Melgarejo JD, **Eap CB**, Staessen JA, Bochud M, Guessous I. Investigating the relations between caffeine-derived metabolites and plasma lipids in two population-based studies *Mayo Clinic Proceedings* 2021 Dec;96(12):3071-3085
- 24) Piras M, Dubath C, Gholam M, Laaboub N, Grosu C, Gamma F, Solida A, Plessen JK, A von Gunten, Conus P, **Eap CB**. Risperidone's daily dose effects on weight and other metabolic parameters: a prospective cohort study. *J Clin Psy* 83(4) 2022 (doi.org/10.4088/JCP.21m14110)

- 25) Dubath C, Gholam-Rezaee M, Sjaarda J, Levier A, Saigi-Morgui N, Delacrétaz A, Glatard A, Panczak R, Correll CU, Solida A, Plessen KJ, von Gunten A, Kutalik Z, Conus P, **Eap CB**. Socio-economic position as a moderator of cardiometabolic outcomes in patients receiving psychotropic treatment associated with weight gain: results from a prospective 12-month inception cohort study and a large population based cohort. *Translational Psychiatry* 2021 Jun 26;11(1):360
- 26) Alameda L, Levier A, Gholam-Rezaee M, Golay P, Vandenberghe F, Delacrétaz A, Baumann P, Glatard A, Dubath C, Herane-Vives A, Rodriguez V, Solida A, Do KQ, **Eap CB**, Conus P. Psychological trauma occurring during adolescence is associated with an increased risk of greater waist circumference in early psychosis patients treated with psychotropic medication. *Plos One* 15(12):e0242569.
- 27) Delacrétaz A, Glatard A, Dubath C, Gholam-Rezaee M, Gamma F, von Gunten A, Conus P, **Eap CB**. Valproate is associated with decrease of high-density lipoprotein cholesterol levels in the psychiatric population. *Basic & Clinical Pharmacology & Toxicology* 2021;129:26-35
- 28) Rios-Leyvraz M, Bochud M, Tabin R, Genin B, Russo M, **Eap CB**, Bovet P, Chiolero A. Monitoring caffeine intake in children with a questionnaire and urine collection: a cross-sectional study in a convenience sample in Switzerland. *European Journal of Nutrition* 2020;59(8):3537-43
- 29) Weisskopf E, Guidi M, Fischer CJ, Bickle Graz M, Beaufiles E, Nguyen KA, Morisod Harari M, Rouiller S, Rothenburger S, Gaucherand P, Kassai-Koupai B, Borradori Tolsa C, Epiney M, Tolsa JF, Vial Y, Hascoët JM, Claris O, **Eap CB**, Panchaud A, Csajka C. A population pharmacokinetic model for escitalopram and its major metabolite in depressive patients during the perinatal period: prediction of infant drug exposure through breast milk. *Br J Clin Pharmacol* 2020;86:1642-1653
- 30) Glatard A, Guidi M, Delacrétaz A, Dubath C, Grosu C, Laaboub N, von Gunten A, Conus P, Csajka C*, **Eap CB*** Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin concentrations and Body Weight Gain by Pharmacokinetic-Pharmacodynamic Analyses. *Joint corresponding author. *Clin Pharmacokinet.* 2020 Mar;59(3):371-382. **Facteur d'impact 4.7 (2018)**
- 31) Dubath C, Delacrétaz A, Glatard A, Vollenweider P, Preisig M, Richard-Lepouriel H, Hasler R, Gamma F, Solida A, Thonney J, Fassassi S, von Gunten A, Conus P, **Eap CB**. Evaluation of cardiometabolic risk in a large psychiatric cohort and comparison with a population-based sample in Switzerland. *J Clin Psychiatry* 81:3 May/June 2020
- 32) Baumann P, **Eap CB**, Gastpar M. The effect of perazine on the CYP2D6- and CYP2C19-phenotypes as measured by the dextromethorphan and mephenytoin tests in psychiatric patients. *Basic & Clinical Pharmacology & Toxicology* 2020; 126:444-447
- 33) Kandera S, Pisanu C, Bandstein M, Jonsson J, Castela E, Pisits G, Gholam-Rezaee M, **Eap CB**, Preisig M, Schiöth HB, Mwinyi J. A pharmacogenetic risk score for the evaluation of major depression severity under treatment with antidepressants. *Drug Development Research* 2020 Feb;81(1):102-113. **Facteur d'impact 1.7 (2018)**
- 34) Rochat C, **Eap CB**, Bochud M, Chatelan A. Caffeine consumption in Switzerland: results from the first national nutrition survey menuCH. *Nutrients* 2019 Dec 20;12(1). pii: E28 **Facteur d'impact 4.2 (2018)**
- 35) Delacrétaz A, Glatard A, Dubath C, Gholam-Rezaee M, Sanchez-Mut JV, Gräff J, von Gunten A, Conus P, **Eap CB**. Psychotropic drug-induced genetic-epigenetic modulation of CRT1 gene is associated with early weight gain in a prospective study of psychiatric patients. *Clinical Epigenetics* 2019;11:198. **Facteur d'impact 5.5 (2018)**
- 36) Ansermot N, Bochatay M, Schläpfer J, Gholam M, Gonthier A, Conus P, **Eap CB**. Prevalence of ECG abnormalities and risk factors for QTc interval prolongation in hospitalized psychiatric patients. *Therapeutic Advances in Psychopharmacology* 2019, Vol 9: 1-13 DOI: 10.1177/2045125319891386. **Facteur d'impact 3.0 (2018)**
- 37) Courlet P, Guidi M, Glatard A, Alves Saldanha S, Cavassini M, Buclin T, Marzolini C, **Eap CB**, Decosterd LA, Csajka C and the Swiss HIV Cohort Study. Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment. *Br J Clin Pharmacol.* 2019;85(9):2022-2032. **Facteur d'impact 3.9 (2018)**.
- 38) Glatard A, Guidi M, Dobrinas M, Cornuz J, Csajka C* and **Eap CB***. Influence of body weight and UGT2B7 polymorphism on varenicline exposure in a cohort of smokers from the general population. * Equal contribution. *Eur J Clin Pharmacol* 2019; 75(7):939-949. **Facteur d'impact 2.8 (2018)**
- 39) Delacrétaz A, Vandenberghe F, Glatard A, Dubath C, Levier A, Gholam-Rezaee M, Holzer L, Ambresin A-E, Conus P, **Eap CB**. Lipid disturbances in adolescent treated with second-generation antipsychotics: Clinical determinants of plasma lipid worsening and new-onset hypercholesterolemia. *J Clin Psychiatry* 80:3, May/June 2019. **Facteur d'impact 4.0 (2018)**

- 40) Hasan A, Bandelow B, Yatham LN, Berk M, Falkai P, Möller HJ, Kasper S and WFSBP Guideline Task Force Chairs. WFSBP Guideline Task Force Chairs: Michael Bauer, Michael Berk, Marijana Bras, Philippe Courtet, Bruno Dubois, **CB Eap**, Wolfgang Gaebel, Angelos Halaris, Siegfried Kasper, Nick Kates, Walter Kaye, Sidney Kennedy, Henry R. Kranzler, Rupert Lanzenberger, Jeffrey Lieberman, Joel Paris, Georgios Petrides, Dan Rujescu, Thomas Schläpfer, Andrea Schmit, Leo She, Constantin Soldato, Nikos Stefanis, Florence Thibaut, Tanelki Tolga, Josef Zohar. WFSBP guidelines on how to grade evidence of psychiatric and psychosocial treatments. *World J Biol Psychiatry* 2019; Jan 20(1):2-16. **Facteur d'impact 4.0 (2018).**
- 41) Saigi-Morgui N, Quteineh L, Bochud PY, Crettol S, Kutalik Z, Mueller NJ, Binet I, Van Delden C, Steiger J, Mohacsi P, Dufour JF, Soccacal PM, Pascual M, **Eap CB** and the Swiss Transplant Cohort Study. Genetic and clinic predictors of new onset diabetes mellitus after transplantation. *The Pharmacogenomics Journal* 2019; 19:53-64. **Facteur d'impact 3.5 (2018).**
- 42) Quteineh L, Agnieszka W, Bochud PY, Crettol S, Vandenberghe F, Venetz JP, Manuel O, Golshayan D, Lehmann R, Mueller NJ, Binet I, van Delden C, Steiger J, Mohacsi P, Dufour JF, Soccacal PM, Kutalik Z, Marques-Vidal P, Vollenweider P, Recher M, Hess C, von Gunten A, Conus P, Pascual MI, **Eap CB**, on behalf of the Swiss Transplant Cohort Study. Genetic immune and inflammatory markers associated with diabetes in solid organ transplant recipients. *Am J Transplant* 2019;19:238-246. **Facteur d'impact 7.2 (2018).**
- 43) Delacretaz A, Vandenberghe F, Glatard A, Levier A, Dubath C, Ansermot N, Crettol-Wavre S, Gholam-Rezaee M, Guessous I, Bochud M, von Gunten, M, Conus P, **Eap CB**, Association between plasma caffeine and other methylxanthines and metabolic parameters in a psychiatric population treated with psychotropic drugs inducing metabolic disturbances. *Frontiers in Psychiatry* Nov. 2018; 9:573. **Facteur d'impact 3.2 (2018).**
- 44) Ponte B, Pruijm M, Ackermann D, Ehret G, Ansermot N, Staessen J, Vogt B, Pechère-Bertschi A, Burnier M, Martin PY, **Eap CB** Bochud M, Guessous I. Associations of urinary caffeine and caffeine metabolites with arterial stiffness in a large population-based study. *Mayo Clin Proc* 2018; 93(3):586-596. **Facteur d'impact 7.1 (2018).**
- 45) Weisstanner C, Kägi G, Krammer W, **Eap CB**, Wiest R, Missimer JH, Weder BJ. The effect of a single dose of escitalopram on sensorimotor networks. *Brain and Behavior* 2018; 8(6) e00975. **Facteur d'impact 2.1 (2018).**
- 46) Vandenberghe F*, Najjar-Giroud A*, Holzer L, Conus P, **Eap CB***, Ambresin A-E*. Second-generation antipsychotics in adolescent psychiatric patients: metabolic effects and impact of an early weight change to predict longer term weight gain. *Journal of Child and Adolescent Psychopharmacology* 2018; 28(4):258-265. **Facteur d'impact 2.2 (2018).** *equal contribution.
- 47) Ansermot N *, Jordanov V *, Smogur M, Holzer L, **Eap CB**. Psychotropic drug prescription in adolescents: a retrospective study in a Swiss psychiatric university hospital. *Journal of Child and Adolescent Psychopharmacology* 2018;(3):192-204. **Facteur d'impact 2.2 (2018).** *equal contribution.
- 48) Conus P, Fournier M, Xin L, Baumann PS, Ferrari C; Cousins A, Alameda L, Gholam-Rezaee M, Golay P, Jenni R, Wilson Woo T-U, Keshavan MS, **Eap CB**, Wojcik J, Cuenod M, Buclin T, Gruetter R, Seidman LJ, Do KQ. N-Acetyl-Cysteine in a double blind randomized placebo controlled trial: towards biomarker guided treatment in early psychosis. *Schizophrenia Bulletin* 2018; 44(2):317-327. **Facteur d'impact 7.3 (2018).**
- 49) Delacretaz A, Vandenberghe F, Gholam-Rezaee M, Saigi Morgui N, Glatard A, Thonney J, Solida-Tozzi A, Kolly S, Fassassi Gallo S, Baumann P, Zulauff Valloton S, Berney S, Hasler R, Aubry J-M, Ebbing K, von Gunten A, Conus P, **Eap CB**. Early changes of blood lipid levels during psychotropic drug treatment as predictors of long-term lipid changes and of new onset dyslipidemia. *Journal of Clinical Lipidology* 2018; 12(1):219-229. **Facteur d'impact 3.0 (2018).**
- 50) Rossetti C, Sciarra D, Petit J-M, **Eap CB**, Halfon O, Magistretti PJ, Boutrel B and Cardinaux JR. Gender-specific alteration of energy balance and circadian locomotor activity in the *Crtc1* knockout mouse model of depression. *Translational Psychiatry* 2017 Dec 8; 7(12):1269. **Facteur d'impact 4.7 (2017).**
- 51) Delacretaz A, Santos Lagares P, Saigi Morgui N, Vandenberghe F, Glatard A, Gholam-Rezaee M, von Gunten A, Conus P, **Eap CB**. Influence of polygenic risk scores on lipid levels and dyslipidemia in a psychiatric population receiving weight gain-inducing psychotropic drugs. *Pharmacogenetics & Genomics* 2017, 27:464-472. **Facteur d'impact 2.3 (2017).**
- 52) Forni Ognà V, Bassi I, Menetrey I, Muller O, Tousset E, Fontana P, Eeckhout E, **Eap CB**, Vrijens B, Burnier M and Wuerzner G. Comparative long-term effect of three anti-P2Y12 drugs after percutaneous angioplasty: an observational study based on electronic drug adherence monitoring. *Frontiers in Pharmacology* 8:article 738, 2017. **Facteur d'impact 3.8 (2017).**
- 53) Glatard A, Dobrinac M, Gholam-Rezaee M, Lubomirov R, Cornuz J, Csajka C, **Eap CB**. Association of nicotine metabolism and sex with relapse following varenicline and nicotine

- replacement therapy. *Experimental and Clinical Psychopharmacology* 2017; 25(5):353-362. **Facteur d'impact 2.4 (2017).**
- 54) Delacrétaz A*, Zdravovic A*, Vandenberghe F, Saigi Morgui N, Glatard A, Quteineh L, Gholam-Rezaee M, Raffoul W, Laurent-Applegate LA, Jafari P, Gamma F, von Gunten A, Conus P, **Eap CB**. Association of variants of *SH2B1* and of *RABEP1* with worsening of low-density lipoprotein and glucose parameters in patients treated with psychotropic drugs. *Gene* 2017; 628:8-15. **Facteur d'impact 2.5 (2017)** * Equal contribution
 - 55) Sikhayeva NS, Iskakova AA, Saigi-Morgui N, Zholdybaeva EV, Momynaliev KT, **Eap CB**, Ramankulov EM. Association of 28 single nucleotide polymorphisms in type 2 diabetes mellitus in the Kazakh population. *BMC Medical Genetics* 2017;18:76. **Facteur d'impact 1.9 (2017).**
 - 56) Weisskopf E, Panchaud A, Fischer CJ, Bickle Graz M, Morisod Harari M, Beaufils E, Nguyen KA, Gaucherand P, Grosjean D, Rothenburger S, Tolsa J-F, Borradori Tolsa C, Epiney M, Vial Y, Hascoët J-M, Claris O, Csajka C, **Eap CB**, and Ansermot N. Simultaneous determination of selective serotonin reuptake inhibitors and their main metabolites in human breast milk by liquid chromatography-electrospray mass spectrometry. *J Chrom B* 2017; 1057:101-109 DOI: 10.1016/j.jchromb.2017.04.039. **Facteur d'impact 2.4 (2017).**
 - 57) Quteineh L, Bochud PY, Golshayan D, Crettol S, Venetz JP, Manuel O, Kutalik Z, Treyer A, Lehmann R, Mueller NJ, Binet I, Van Delden C, Steiger J, Mohacsi P, Dufour JF, Gasche-Soccal P, Pascual M, **Eap CB** and the Swiss Transplant Cohort Study. *CRTC2* polymorphism as a risk factor for the incidence of metabolic syndrome in patients with solid organ transplantation. *The Pharmacogenomics Journal* 2017 Jan; 17(1):69-75. . **Facteur d'impact 3.8 (2017).**
 - 58) Cornelis MC, Kacprowski T, Menni C, Gustafsson S, Pivin E, Adamski J, Artati A, **Eap CB**, Ehret G, Friedrich N, Ganna A, Guessous I, Homouth G, Lind L, Magnusson PK, Mangino M, Pedersen NL, Pietzner M, Suhre K, Völzke H, Bochud M, Spector TD, Grabe HJ, Ingelsson E. Genome-wide association study of caffeine metabolites provides new insights to caffeine metabolism and dietary caffeine-consumption behavior. *Human molecular Genetics* 2016; 25(4):5472-5482. **Facteur d'impact 5.3 (2016).**
 - 59) Petrovic D, Estoppey Younes S, Pruijm M, Ponte B, Ackermann D, Ehret G, Ansermot N, Mohaupt M, Paccaud F, Vogt B, Pechère-Bertschi A, Martin P-Y, Burnier M, **Eap CB**, Bochud M, Guessous I. Relation of 24-hour urinary caffeine and caffeine metabolite excretions with self-reported consumption of coffee and other caffeinated beverages in the general population. *Nutrition and Metabolism* (2016) 13:81 Doi 10.1186/s12986-016-0144-4. **Facteur d'impact 3.0 (2016).**
 - 60) Forni Ognà V, Menetrey I, Muller O, Tousset E, Guihard L, Fontana P, Eeckout E, **Eap CB**, Vrijens B, Burnier M, Wuerzner G. Effect of long-term adherence to clopidogrel on the VASP-PRI after elective coronary stent implantation: a randomized controlled study. *Br J Clin Pharmacol* 2016 Dec; 82(6):1486-1497. **Facteur d'impact 3.5 (2016).**
 - 61) Csajka C, Crettol S, Guidi M, **Eap CB**. Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid Dependent Patients. *Clin Pharmacokinet* 2016; 55:1521-1533. **Facteur d'impact 5.2 (2016).**
 - 62) Vandenberghe F, Saigi Morgui N, Delacrétaz A, Quteineh L, Crettol S, Ansermot N, Gholam-Rezaee M, von Gunten A, Conus P, **Eap CB**. Prediction of early weight gain during psychotropic treatment using a combinatorial model with clinical and genetic markers. *Pharmacogenetics & Genomics* 2016, 26:547-557. **Facteur d'impact 2.2 (2016).**
 - 63) Saigi-Morgui N, Quteineh L, Bochud PY, Crettol S, Kutalik Z, Wojtowicz A, Bibert S, Beckmann S, Mueller NJ, Binet I, van Delden C, Steiger J, Mohacsi P, Stirnimann G, Soccal PM, Pascual M, **Eap CB** and the Swiss Transplant Cohort Study. Weighted genetic risk scores and prediction of weight gain in Solid Organ Transplant populations. *Plos One* 11(10):e014443, 2016. **Facteur d'impact 2.8 (2016).**
 - 64) Weisskopf E, Panchaud A, Nguyen K A, Hascoët J-M, Csajka C, **Eap CB**, Ansermot N, and the collaborators of the SSRI-Milk study. Stereoselective determination of citalopram and desmethylcitalopram in human plasma and breast milk by liquid chromatography tandem mass spectrometry. *Journal Pharmaceutical Biomedical Analysis* 2016; 131:233-245. **Facteur d'impact 3.3 (2016).**
 - 65) Quteineh L, Preisig M, Rivera M, Milaneschi Y, Castelao E, Gholam-Rezaee M, Vandenberghe F, Saigi-Morgui N, Delacrétaz A, Cardinaux JR, Willemsen G, Boomsma D I, B WJH Penninx, Ching-López A, Conus P, **Eap CB**. Association of *CRTC1* polymorphisms with obesity markers in subjects from the general population with lifetime depression. *Journal of Affective Disorders* 198 (2016) 43–49. **Facteur d'impact 3.4 (2016).**
 - 66) Saigi-Morgui N, Vandenberghe F, Delacrétaz A, Quteineh L, Gholam-Rezaee M, Aubry JM, von Gunten A, Kutalik Z, Conus P, **Eap CB**. Association of Genetic Risk Scores (GRS) with Body Mass Index in Swiss psychiatric cohorts. *Pharmacogenetics and Genomics* 2016 May; 26(5):208-217. **Facteur d'impact 2.2 (2016).**

- 67) Marie-Claire C, Crettol S, Cagnard N, Bloch V, Mouly S, Laplanche J-L, Bellivier F, Lépine JP, **Eap CB**, Vorspan F. Variability of response to methadone: genome-wide DNA methylation analysis in two independent cohorts. *Epigenomics* 2016;8(2):181-195. **Facteur d'impact 4.5 (2016).**
- 68) Liu Y, Jann M, Vandenberg C, **Eap CB**, Shamsia SA. Development of an enantioselective assay for simultaneous separation of venlafaxine and O-desmethylvenlafaxine by micellar electrokinetic chromatography-tandem mass spectrometry: Application to the analysis of drug-drug interaction. *J Chrom A* 1420:119-128, 2015. **Facteur d'impact 3.9 (2015).**
- 69) Sakae DY, Marti F, Lecca S, Vorspan F, Martín-García E, Morel LJ, Henrion A, Gutiérrez-Cuesta J, Besnard A, Heck N, Herzog E, Bolte S, Prado VF, Prado MAM, Bellivier F, **Eap CB**, Crettol S, Vanhoutte P, Caboche J, Gratton A, Moquin L, Giros B, Maldonado R, Daumas S, Mameli M, Jamain S, El Mestikawy S. The absence of VGLUT3 predisposes to cocaine abuse by increasing dopamine and glutamate signaling in the nucleus accumbens. *Molecular Psychiatry* 2015 Nov;20(11):1448–1459. **Facteur impact 13.3 (2015).**
- 70) Vandenberghe F, Guidi M, Choong E, von Gunten A, Conus P, Csajka C, **Eap CB**. Genetics-based population pharmacokinetics and pharmacodynamics of risperidone in a psychiatric cohort. *Clinical Pharmacokinetics* 2015: 54:1259–1272. **Facteur impact 4.8(2015).**
- 71) Saigi Morgui N, Vandenberghe F, Delacretaz A, Quteineh L, Choong E, Gholam-Rezaee M, Magistretti P, Aubry J-M, von Gunten A, Preisig M, Castelao E, Vollenweider P, Waeber G, Kutalik Z, Conus P, **Eap CB**. Association of PCK1 with body mass index and other metabolic features in patients with psychotropic treatments. *J Clin Psychopharmacol* 2015 Oct;35(5):544-52. **Facteur d'impact 3.0 (2015).**
- 72) Delacretaz A, Preisig M, Vandenberghe F, Saigi Morgui N, Quteineh L, Choong E, Gholam-Rezaee M, Kutalik Z, Magistretti P, Aubry JM, von Gunten A, Castelao E, Vollenweider P, Waeber G, Conus P, **Eap CB**, Influence of *MCHR2* and *MCHR2-AS1* genetic polymorphisms on body mass index in psychiatric patients and in subjects from the general population with present or past atypical depression. *Plos One* 2015 October 13 ; 10(10) :e0139155. **Facteur d'impact 3.1 (2015).**
- 73) Vandenberghe F, Gholam Rezaee M, Saigi Morgui N, Delacretaz A, Choong E, Solida A, Kolly S, Thonney J, Fassassi S, Ahmed H, von Gunten A, Conus P, **Eap CB**. Importance of early weight gain changes to predict long term weight gain during psychotropic drug treatment. *J Clin Psychiatry* 2015(76):11:e1417-e1423. **Facteur d'impact 5.4 (2015).**
- 74) Quteineh L, Vandenberghe F, Saigi Morgui N, Delacretaz A, Choong E, Gholam-Rezaee M, Magistretti P, Bondolfi G, von Gunten A, Preisig M, Castelao E, Vollenweider P, Waeber G, Bochud M, Kutalik Z, Conus P, **Eap CB**. Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments. *Pharmacogenetics & Genomics* 2015, 25(5):246-258. **Facteur d'impact 2.9 (2015).**
- 75) Guessous I, Pruijm M, Ponte B, Ackermann D, Ehret G, Ansermot N, Vuistiner P, Staessen JA, Gu Y-M, Paccaud F, Mohaupt MG, Vogt B, Pechere-Berstchi A, Martin PY, Burnier M, **Eap CB**, Bochud M. Associations of ambulatory blood pressure with urinary caffeine and caffeine metabolites excretions. *Hypertension* 2015;65:691-696. **Facteur d'impact 6.4 (2015).**
- 76) Diaz FJ, **Eap CB**, Ansermot N, Crettol S, Spina E, de Leon J. Can valproic acid be an inducer of clozapine metabolism? *Pharmacopsychiatry* 2014;47:89-96. **Facteur d'impact 1.9 (2014).**
- 77) Noetzli M, Guidi M, Ebbing K, Eyer S, Wilhelm L, Michon A, Thomazic V, Stancu I, Alnawaqil A-M, Bula C, Zumbach S, Gaillard M, Giannakopoulos P, Von Gunten A, Csajka C, **Eap CB**. Population pharmacokinetic approach to evaluate the effect of *CYP2D6*, *CYP3A*, *ABCB1*, *POR* and *NR1I2* genotypes on donepezil clearance **Br J Clin Pharmacol** 2014; 78(1):135-144. **Facteur d'impact 3.9 (2014).**
- 78) Gradinaru J, Vullioud A, **Eap CB**, Ansermot N. Quantification of typical antipsychotics in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry for therapeutic drug monitoring *Journal of Pharmaceutical and Biomedical Analysis* 2014; 88:36-44. **Facteur d'impact 3.0 (2014).**
- 79) Holzer L, Pihet S, Moses Passini C, Feijo I, Camus D, **Eap CB**. Substance use in adolescent psychiatric outpatients: self-report, healthcare providers's clinical impressions and urine screening *J of Child and Adolescent substance abuse* (2014) 23:1-8. **Facteur d'impact 0.6 (2014).**
- 80) Khazaal Y, Preisig M, Chatton A, Kaufmann N, Bilancioni R, **Eap CB**. Use of high doses of quetiapine in bipolar disorder episodes are not linked to high activity of cytochrome P4503A4 and/or cytochrome P4502D6. *Psychiatric Quarterly* (2013) 84: 329-335. **Facteur d'impact 1.3 (2013).**
- 81) Ansermot N, Brawand Amey M, Kottelat A, **Eap CB**. Fast quantification of ten psychotropic drugs and metabolites in human plasma by ultra high pressure liquid chromatography tandem mass spectrometry for therapeutic drug monitoring. *J Chrom A* 2013; 1292:160–172. **Facteur d'impact 4.3 (2013).**

- 82) Noetzli M, Guidi M, Ebbing K, Eyer S, Zumbach S, **Eap CB**. Relationship of CYP2D6, CYP3A, POR and ABCB1 genotypes with galantamine plasma concentrations. *Therapeutic Drug Monitoring* 2013; 35:270-275. **Facteur d'impact 1.9 (2013)**.
- 83) Dobrinas M, Cornuz J, **Eap CB**. Pharmacogenetics of CYP1A2 activity and inducibility in smokers and exsmokers. *Pharmacogenetics & Genomics* 2013, 23:286-292. **Facteur d'impact 3.5 (2013)**.
- 84) Noetzli M, Guidi M, Ebbing K, Eyer S, Wilhelm L, Michon A, Thomazic V, Alnawaqil AM, Maurer S, Zumbach S, **Eap CB**. Population pharmacokinetic study of memantine: effects of clinical and genetic factors. *Clinical Pharmacokinetics* 2013; 52:211-223. **Facteur d'impact 5.5 (2013)**.
- 85) Dobrinas M, Crettol S, Oneda B, Lahyani R, Rotger M, Choong E, Lubomirov R, Csajka C, **Eap CB**. Contribution of *CYP2B6* alleles to explain extreme (S)-methadone plasma levels: a *CYP2B6* gene sequencing study. *Pharmacogenetics & Genomics* 2013, 23:84–93. **Facteur d'impact 3.5 (2013)**.
- 86) Choong E, Quteineh L, Cardinaux J-R, Gholam-Rezaee M, Vandenberghe F, Dobrinas M, Bondolfi G, Etter M, Holzer L, Magistretti P, Von Gunten A, Preisig M, Vollenweider P, the GIANT Consortium, the ODEX team, Beckmann JS, Pralong FP, Waeber G, Kutalik Z, Conus P, Bochud M, **Eap CB**. Influence of *CRTC1* polymorphisms on body mass index and fat mass in psychiatric patients and in the general adult population. *JAMA Psychiatry* 2013; 70(10):1011-1019 (old name: *Archives of General Psychiatry*) doi:10.1001/jamapsychiatry.2013.187.
- 87) Choong E, Polari A, Kamdem RH, Gervasoni N, Spisla C, Jaquenoud Sirot E, Giacometti Bickel G, Bondolfi G, Conus P, **Eap CB**. Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and Pregnane X receptor on risperidone exposure and drug-induced side-effects. *J Clin Psychopharmacol* 2013; 33: 289-298. **Facteur d'impact 3.8 (2013)**.
- 88) Haouala A, Widmer N, Montermurro M, Leyvraz S, Buclin T, **Eap CB**, Decosterd LA, Csajka C. Prediction of free imatinib concentrations based on total plasma levels in gist patients. *Br J Clin Pharmacol* 75:4; 1007-18 (2013). **Facteur d'impact 3.7 (2013)**.
- 89) Lüthi G, Blangy V, **Eap CB**, Ansermot N. Buprenorphine and norbuprenorphine quantification in human plasma by simple protein precipitation and ultra-high-pressure liquid chromatography tandem mass spectrometry. *Journal of Pharmaceutical and Biomedical Analysis* 77 (2013) 1– 8. **Facteur d'impact 2.8 (2013)**.
- 90) Fayet Mello A, Buclin T, Guignard N, Cruchon S, Cavassini M, Grawe C, Gremlich E, Aebi Popp K, Schmid F, **Eap CB**, Telenti A, Biollaz J, Decosterd A L, Martinez de Tejada B. Free and total plasma concentrations of lopinavir, atazanavir, and nevirapine during pregnancy, at delivery and post-partum. *Antiviral therapy* 2013; 18(2):171-182. **Facteur d'impact 3.1 (2013)**.
- 91) Noetzli M, Ansermot N, Dobrinas M, **Eap CB**. Simultaneous determination of antideementia drugs in human plasma: procedure transfer from HPLC-MS to UPLC-MS/MS. *J Pharmaceutical Biomedical Analysis* 64-65:16-25, 2012. **Facteur d'impact 2.9 (2012)**.
- 92) Ansermot N, Brawand Amey M, **Eap CB**, Simultaneous quantification of selective serotonin reuptake inhibitors and metabolites in human plasma by liquid chromatography-electrospray mass spectrometry for therapeutic drug monitoring. *J Chrom B* 885– 886 (2012) 117– 130. **Facteur d'impact 2.5 (2012)**.
- 93) Jaquenoud Sirot E, Harenberg S, Vandiel P, Mendonça Lima C A, Perrenoud P, Kemmerling K, Zullino DF, Hilleret H, Crettol S, Jonzier-Perey M, Powell Golay K, Brocard M, **Eap CB**, Baumann P. Multicenter study on the clinical effectiveness, pharmacokinetics and pharmacogenetics of mirtazapine in depression. *J Clin Psychopharmacol*, 32, 622-29 (2012). **Facteur d'impact 3.5 (2012)**.
- 94) Loayza N, Crettol S, Riquier F, **Eap CB**. Adherence to antidepressant treatment: what the doctor thinks and what the patient says. *Pharmacopsychiatry* 45: 204–207, 2012. **Facteur d'impact 2.1 (2012)**.
- 95) Guessous I, Dobrinas M, Kutalik Z, Pruijm M, Ehret G, Maillard M, Bergmann S, Beckmann JS, Cusi D, Rizzi F, Cappucio F, Cornuz J, Paccaud F, Mooser V, Gaspoz JM, Waeber G, Burnier M, Vollenweider P, **Eap CB**, Bochud M. Caffeine intake, and CYP1A2 variants associated with high caffeine intake, protect non-smokers from hypertension. *Human Molecular Genetics* 21(14):3283-3292, 2012. **Facteur d'impact 7.7 (2012)**.
- 96) Dobrinas M, Cornuz J, Pedrido L, **Eap CB**. Influence of cytochrome P450 oxidoreductase (POR) genetic polymorphisms on CYP1A2 activity and inducibility by smoking. *Pharmacogenetics & Genomics* 22(2):143-151, 2012. **Facteur d'impact 3.6 (2012)**.
- 97) Choong E, Bondolfi G, Etter M, Jermann F, Aubry JM, Bartolomei J, Gholam-Rezaee M, **Eap CB**. Psychotropic drug induced weight gain and other metabolic complications in a Swiss Psychiatric population. *J Psychiatric Research* 46:540-548, 2012. **Facteur d'impact 4.0 (2012)**.
- 98) Dobrinas M, Choong E, Noetzli M, Cornuz J, Ansermot N, **Eap CB**. Quantification of nicotine, cotinine, trans-3'-hydroxycotinine and varenicline in human plasma by a sensitive and specific

- UPLC-tandem mass spectrometry for a clinical study on smoking cessation. *J Chrom B* 879: 3574-82, 2011. **Facteur d'impact 2.9 (2011).**
- 99) Dobrinas M, Cornuz J, Oneda B, Kohler Serra M, Puhl M, **Eap CB**. Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity. *Clin Pharmacol Ther* 90(1) :117-125, 2011. **Facteur d'impact 6.0 (2011).**
 - 100) Noetzi M, Choong E, Ansermot N, **Eap CB**. Simultaneous determination of antimentia drugs in human plasma for therapeutic drug monitoring. *Therapeutic Drug Monitoring* 33(2): 227-38, 2011. **Facteur d'impact 2.5 (2011).**
 - 101) Choong E, Rudaz S, Kottelat A, Haldemann S, Guillaume D, Veuthey JL, **Eap CB**. Quantification of 4 antidepressants and a metabolite by LC-MS for therapeutic drug monitoring. *J Chrom B* 879: 1544-50, 2011. **Facteur d'impact 2.9 (2011).**
 - 102) Pelet A, Favrat B, Cavassini M, **Eap CB**, Besson J, Monnat M. Usefulness of methadone plasma concentration measurement in patients receiving nevirapine or efavirenz. *Am J Drug Alcohol Abuse* 37:264-8, 2011.
 - 103) Oneda B, Crettol S, Bochud M, Besson J, Croquette-Krokar M, Hämmig R, Monnat M, Preisig M, **Eap CB**. β -arrestin2 influences the response to methadone in opioid dependent patients. *The Pharmacogenomics Journal* 11:258-266, 2011. **Facteur d'impact 4.5 (2011).**
 - 104) Nikisch G, Baumann P, Oneda B, Kessler B, Weisser H, Mathé AA, Takashi Y, Kehr J, Wiedemann G, **Eap CB**. Cytochrome *P450* and *ABCB1* genetics: Association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study. *J Psychopharmacol* 25(7):896-907, 2011. **Facteur d'impact 3.0 (2011).**
 - 105) Ansermot N, Albayrak Ö, Schläpfer J, Crettol S, Croquette-Krokar M, Bourquin M, Déglon JJ, Faouzi M, Scherbaum N, **Eap CB**. Substitution of (R,S)-methadone by (R)-methadone: impact on QTc interval. *Archives of Internal Medicine* 170(6): 529-36 Mar 22; 2010. **Facteur d'impact 10.6 (2010).**
 - 106) Samer CF; Daali Y; Wagner M; Hopfgartner G; **Eap CB**; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. *Br J Pharmacol* 160: 907-18, 2010. **Facteur d'impact 3.1 (2010).**
 - 107) Samer CF; Daali Y; Wagner M; Hopfgartner G; **Eap CB**; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA. Genetic polymorphism and drug interactions modulating CYP2D6 and CYP3A activities have a major impact on oxycodone analgesic efficacy and safety. *Br J Pharmacol* 160: 919-30, 2010. **Facteur d'impact 3.1 (2010).**
 - 108) Choong E, Rudaz S, Kottelat A, Guillaume D, Veuthey JL, **Eap CB**. Therapeutic drug monitoring of 7 psychotropic drugs and 4 metabolites in human plasma by HPLC-MS. *J Pharmaceut Biomed Analysis* 50: 1000-8 (2009). **Facteur d'impact 2.5 (2009).**
 - 109) Oneda B, Crettol S, Jaquenoud E, Bochud M, Ansermot N, **Eap CB**. The P450 oxidoreductase is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. *Pharmacogenetics and Genomics* 19:877-83, 2009 **Facteur d'impact 4.0 (2009).**
 - 110) Hallinan R, Crettol S, Agho K, Attia J, Besson J, Croquette-Krokar M, Hämmig R, Déglon JJ, Byrne A, Somogyi A, **Eap CB**. Cannabis and benzodiazepines as determinants of methadone trough plasma concentration variability in maintenance treatment: a transnational study. *Eur J Clin Pharmacol* 65:1113-1120 (2009). **Facteur d'impact 2.7 (2009).**
 - 111) Ansermot N, Rudaz S, Brawand-Amey M, Fleury-Souverain S, Veuthey JL, **Eap CB**. Validation and long-term evaluation of a modified on-line chiral analytical method for therapeutic drug monitoring of (R,S)-methadone in clinical samples. *J Chromatography B* 877:2301-2307 (2009). **Facteur d'impact 2.8 (2009).**
 - 112) Jaquenoud Sirot E, Knezevic B, Perla Morena G, Harenberg S, Oneda B, Crettol S, Ansermot N, Baumann P, **Eap CB**. ABCB1 and cytochromes P450 polymorphisms: clinical pharmacogenetics of clozapine. *J Clin Psychopharmacol* 29:319-26 (2009). **Facteur d'impact 5.1 (2009).**
 - 113) Arab-Alameddine M, Buclin T, Rotger M, Lubomirov R, Di Iulio J, Cavassini M, Fayet A, Décosterd LA, **Eap CB**, Biollaz J, Telenti A, Csajka C and the Swiss HIV Cohort Study. Population Pharmacokinetic and Pharmacogenetic Analysis of Efavirenz in HIV-1 Infected Individuals. *Clin Pharmacol Ther* 85:485-94 (2009). **Facteur d'impact 7.0 (2009).**
 - 114) Di Iulio J, Rotger M, Fayet A, Lubomirov R, Arab-Alameddine M, Cavassini M, Furrer HJ, Günter HF, Colombo S, Csajka C, **Eap CB**, Decosterd LA, Telenti A. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. *Pharmacogenetics & Genomics* 19:300-9 (2009). **Facteur d'impact 4.0 (2009).**
 - 115) Nikisch G, **Eap CB**, Baumann P. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: A pilot study *Pharmacological Research* 58:344-7, 2008. **Facteur d'impact 3.3 (2008).**

- 116) Crettol S, Venetz JP, Fontana M, Aubert JD, Pascual M, **Eap CB**. CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. *Ther Drug Monitor* 30(6):689-99 (2008). **Facteur d'impact 2.4 (2008)**.
- 117) Daghli MRC, Williams TM, Wilson SJ, Taylor LG, **Eap CB**, Augsburger M, Giroud C, Brooks DJ, Myles JS, Grasby P, Lingford-Hughes AR, Nutt DJ. Brain dopamine response in human opioid addiction. *Br J Psychiatry* 193:65-72 (2008). **Facteur d'impact 5.1 (2008)**.
- 118) Zullino D, Krenz S, **Eap CB**, Bertolini M, Khan R. Over- and underreporting of recent drug use in subjects entering an inpatient detoxification unit. *Eur J Med Res* 13(1):15-20 (2008). **Facteur d'impact 1.0 (2008)**.
- 119) Fayet A, Beguin A, Martinez de Tejada B, Colombo S, Cavassini M, Gerber S, **Eap CB**, Telenti A, Buclin T, Biollaz J, Decosterd LA. Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in free fraction *Ther Drug Monitor* 30; 511-22, 2008. **Facteur d'impact 2.4 (2008)**.
- 120) Bochud M, **Eap CB**, Maillard M, Jonson T, Vollenweider P, Bovet P, Elston RC, Bergman S, Beckmann JS, Waterworth D, Moser V, Gabriel A, Burnier M. Associations of ABCB1 genetic variants with renal function in Africans and Caucasians. *BMC medical genomics* 1:21 (2008).
- 121) Gex-Fabry M, **Eap CB**, Oneda B, Gervasoni N, Aubry JM, Bondolfi G, Bertschy G. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. *Ther Drug Monitor* 30:474-82 (2008). **Facteur d'impact 2.4 (2008)**.
- 122) Crettol S, Venetz JP, Fontana M, Aubert JD, Ansermot N, Fathi M, Pascual M, **Eap CB**. Influence of ABCB1 genetic polymorphism on cyclosporine intracellular concentrations in transplant recipients. *Pharmacogenetics & Genomics* 18:307-315, 2008. **Facteur d'impact 4.4 (2008)**.
- 123) Crettol S, Déglon JJ, Besson J, Croquette-Krokar M, Hämmig R, Gothuey I, Monnat M, Preisig M, **Eap CB**. Association of dopamine and opioid receptor gene polymorphisms with response to methadone during maintenance treatment. *Progress Neuro Psychopharmacol Biol Psy* 32:1722-27 (2008). **Facteur d'impact 2.6 (2008)**.
- 124) Saraeva RB, Paskaleva ID, Doncheva E, **Eap CB**, Ganev VS. Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements. *J Clin Pharm Ther* 32:641-9, 2007. **Facteur d'impact 1.4 (2007)**.
- 125) Crettol S, Digon P, Powell Golay K, Brawand-Amey M, **Eap CB**. In vitro P-glycoprotein-mediated transport of (R)- and (S)-methadone, LAAM and their main metabolites. *Pharmacology* 80:304-311, 2007. **Facteur d'impact 1.2 (2007)**.
- 126) Sporkert F, Augsburger MP, Giroud C, Brossard C, **Eap CB**, Mangin P. Determination and distribution of clonidine (Entumine®) in human plasma, post-mortem blood and tissues samples from clonidine-treated patients and from autopsy cases. *Forensic Science International* 170(2-3) 193-199, 2007. **Facteur d'impact 2.0 (2007)**.
- 127) Uehlinger C, Crettol S, Chassot P, Brocard M, Koeb L, Brawand-Amey M, **Eap CB**. Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients. *J Clin Psychopharmacol* 27(3):273-278, 2007. **Facteur d'impact 3.9 (2007)**.
- 128) Le Bloc'h Y, Baumann P, Stigler M, **Eap CB**, Zullino D. Efficacy and tolerability of quetiapine in Cluster B Personality Disorder : an open label study. *International Journal of Psychiatry in Clinical Practice* 11(2) 123-8, 2007. **Facteur d'impact 0.4 (2007)**.
- 129) **Eap CB**, Crettol S, Rougier JS, Schläpfer J, Correa-Sintra L, Déglon JJ, Besson J, Croquette-Krokar M, Abriel H. Stereoselective block of hERG channel and by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers *Clin Pharmacol Ther* 81:719-728, 2007. **Facteur d'impact 8.0 (2007)**.
- 130) Gex-Fabry M, Gervasoni N, Bondolfi G, Aubry JM, **Eap CB**, Bertschy G. Time course of response to paroxetine: influence of age, episode duration and plasma level. *Prog Neuro Psychopharmacol & Biol Psy* 31(4) 892-900, 2007. **Facteur d'impact 2.8 (2007)**.
- 131) **Eap CB**, Bochud M, Elston RC, Maillard M, Bovet P, Nussberger J, Schild L, Shamlaye C, Burnier M. The CYP3A5 and ABCB1 genes influence blood pressure and response to treatment, and their effect is modified by salt. *Hypertension* 49(5) 1007-1014, 2007. **Facteur d'impact 7.2 (2007)**.
- 132) Crettol S, Déglon JJ, Besson J, Croquette-Krokar M, Hämmig R, Gothuey I, Monnat M, **Eap CB**. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. *Clin Pharmacol Ther* 80(6) 668-81, 2006. **Facteur d'impact 8.1 (2006)**.
- 133) Colombo S, Buclin T, Decosterd LA, Telenti A, Furrer H, Lee BL, Biollaz J, **Eap CB**. Orosomucoid (Alpha 1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. *Clin Pharmacol Ther* 80(4) 307-18, 2006. **Facteur d'impact 8.1 (2006)**.
- 134) Widmer N, Decosterd LA, Csajka C, Leyvraz S, Duchosal MA, Rosselet A, Rochat B, **Eap CB**, Henry H, Biollaz J, Buclin T. Population pharmacokinetics of imatinib and the role of alpha1-acid

- glycoprotein. *Br J Clin Pharmacol* 62(1) 97-112, 2006. Erratum *Br J Clin Pharmacol* DOI:10.1111/j.1365-2125.2010.03738.x. **Facteur d'impact 2.7 (2006).**
- 135) Holzer L and **Eap CB**. Risperidone induced symptomatic hyperprolactinaemia in adolescents. *J Clin Psychopharmacol* 26(2) 167-171, 2006. **Facteur d'impact 4.6 (2006).**
- 136) Bochud M, **Eap CB**, Elston RC, Bovet P, Maillard M, Schild L, Shamlaye C, Burnier M. Association of CYP3A5 genotypes with blood pressure and renal function in African families. *J Hypertension* 24(5) 923-929, 2006. **Facteur d'impact 4.0 (2006).**
- 137) Bonsack C, Camus D, Kaufmann N, Spagnoli J, Aubert AC, Besson J, Baumann P, Borgeat F, Gillet M, **Eap CB**. Prevalence of drug use in a Swiss Psychiatric hospital: interview reports and urine screening. *Addictive Behaviors* 31(7) 1252-8, 2006. **Facteur d'impact 1.8 (2006).**
- 138) Crettol S, Déglon JJ, Besson J, Croquette-Krokar M, Gothuey I, Hämmig R, Monnat M, Hüttemann H, Baumann P, **Eap CB**. Methadone enantiomer plasma levels, CYP2B6, CYP2C9 and CYP2C19 genotypes, and response to treatment. *Clin Pharmacol Ther* 2005;78(6) 593-604. **Facteur d'impact 7.5 (2005).**
- 139) de Medonça Lima C, Baumann P, Brawand-Amey M, Brogli C, Jacquet S, Cochard N, Powell Golay K, **Eap CB**. Effects of age and gender on citalopram and desmethylcitalopram steady-state plasma concentrations in adults and elderly depressed patients. *Progress in Neuro-Psychopharmacology & Biological Psychiatry* 29(6) 952-956, 2005. **Facteur d'impact 2.8 (2005).**
- 140) Nikisch G, Mathé AA, Czernik A, Thiele J, Bohner J, **Eap CB**, Agren A, Baumann P. Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with (S)-citalopram concentration in plasma and cerebrospinal fluid (CSF) and clinical response. *Psychopharmacology* 181(4) 751-60, 2005. **Facteur d'impact 4.0 (2005).**
- 141) Bondolfi G, Morel F, Crettol S, Rachid F, Baumann P, **Eap CB**. Increased clozapine plasma concentrations and side effects induced by smoking cessation in two CYP1A2 genotyped patients. *Ther Drug Monitor* 27(4) 539-543, 2005. **Facteur d'impact 2.7 (2005).**
- 142) Chevalley AF, Besson J, Croquette-Krokar M, Davidson C, Dubois JA, Uehlinger C, **Eap CB**. Prevalence of the injection of methadone in three Swiss cities. *La Presse Médicale* 34(11) 776-80, 2005. **Facteur d'impact 0.4 (2005).**
- 143) Fellay J, Marzolini C, Decosterd L, Powell Golay K, Baumann P, Buclin T, Telenti A, **Eap CB**. Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. *Eur J Clin Pharmacol* 60(12) 865-73, 2005. **Facteur d'impact 2.3 (2005).**
- 144) Nikisch G, Agren H, **Eap CB**, Czernik A, Baumann P, Mathé AA. Neuropeptide Y and corticotropin-releasing hormone in CSF marks response to antidepressive treatment with citalopram. *Int J Neuropsychopharmacol* 8:403-410, 2005. **Facteur d'impact 4.0 (2005).**
- 145) Haller-Gloor F, **Eap CB**, Turgeon J, Baumann P. High-dose venlafaxine treatment in a depressed patient with a genetic CYP2D6 deficiency. *International J Psych Clin Pract* 8(3):191-195, 2004. **Facteur d'impact 0.3 (2004).**
- 146) Giroud C, Katarzyna M, Sporkert F, **Eap CB**, Augsburg M, Cardinal P, Mangin P. A fatal overdose of cocaine associated with coingestion of marijuana, buprenorphine, and fluoxetine. Body fluid and tissue distribution of cocaine and its metabolites determined by hydrophilic interaction chromatography – mass spectrometry (HILIC-MS). *J Anal Toxicol* 28: 464-474, 2004. **Facteur d'impact 1.7 (2004).**
- 147) Benmebarek M, Devaud C, Gex-Fabry M, Powell Golay K, Brogli C, Baumann P, Gravier B, **Eap CB**. Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone. *Clin Pharmacol Ther* 2004; 76(1): 55-63. **Facteur d'impact 6.8 (2004).**
- 148) **Eap CB**, Buclin T, Cucchia G, Zullino D, Hustert E, Bleiber G, Powell Golay K, Aubert AC, Baumann P, Telenti A, Kerb R. Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. *Eur J Clin Pharmacol* 60(4): 237-246, 2004. **Facteur d'impact 2.1 (2004).**
- 149) **Eap CB**, Buclin T, Hustert E, Bleiber G, Powell Golay K, Aubert AC, Baumann P, Telenti A, Kerb R. Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. *Eur J Clin Pharmacol* 60(4):231-236, 2004. **Facteur d'impact 2.1 (2004).**
- 150) **Eap CB**, Bouchoux G, Powell Golay K, Baumann P. Determination of human plasma levels of levo-alpha-acetylmethadol (LAAM) and its metabolites by gas chromatography-mass spectrometry. *J Chromatogr B* 805(1):141-146, 2004. **Facteur d'impact 2.2 (2004).**
- 151) Nikisch G, Mathé AA, Czernik A, **Eap CB**, Jiménez-Vasquez P, Brawand-Amey M, Baumann P. Stereoselective metabolism of citalopram in plasma and cerebrospinal fluid (CSF) of depressive patients: relationship with 5-HIAA in CSF and clinical response. *J Clin Psychopharmacol* 24(3): 283-290, 2004. **Facteur d'impact 4.4 (2004).**

- 152) **Eap CB**, Fellay J, Buclin T, Bleiber G, Powell Golay K, Brocard M, Baumann P, Telenti A. CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene. *Pharmacogenetics* 14(4):255-260, 2004. **Facteur d'impact 6.4 (2004).**
- 153) Ciusani E, Zullino D, **Eap CB**, Brawand-Amey M, Broccard M, Baumann P. Combination therapy with venlafaxine and carbamazepine in depressive patients non-responding to venlafaxine: pharmacokinetic and clinical aspects. *Journal of Psychopharmacology* 18(4):559-66, 2004. **Facteur d'impact 2.3 (2004).**
- 154) Paus E, Jonzier-Perey M, Cochard M, **Eap CB**, Baumann P. Chirality in the new generations of antidepressants: Stereoselective analysis of the enantiomers of mirtazapine, N-demethylmirtazapine and 8-hydroxymirtazapine by LC-MS. *Ther Drug Monitor* 26:366-374, 2004. **Facteur d'impact 2.8 (2004).**
- 155) Giroud C, Horisberger B, **Eap CB**, Augsburg M, Ménétrey A, Baumann P, Mangin P. Death following acute poisoning by moclobemide. *Forensic Sci Int* 140 (1):101-107, 2004. **Facteur d'impact 1.4 (2004).**
- 156) **Eap CB**, Bender S, Jaquenoud Sirot E, Cucchia G, Jonzier-Perey M, Baumann P, Allorge D, Broly F. Non-response to clozapine and ultrarapid CYP1A2 activity clinical data and analysis of CYP1A2 gene. *J Clin Psychopharmacol* 24:214-219, 2004. **Facteur d'impact 4.4 (2004).**
- 157) **Eap CB**, Bouchoux G, Powell Golay K, Baumann P. Determination of picogram levels of midazolam, and 1- and 4-hydroxymidazolam in human plasma by gas chromatography-negative chemical ionisation-mass spectrometry. *J Chromatogr B* 802(2):339-345, 2004. **Facteur d'impact 2.2 (2004).**
- 158) Souverain S, **Eap CB**, Veuthey JL, Rudaz S. Automated LC-MS method for the fast stereoselective determination of methadone in plasma. *Clinical Chemistry and Laboratory medicine* 41(12):1615-1621, 2003. **Facteur d'impact 1.5 (2003).**
- 159) Shinderman M, Maxwell S, Brawand-Amey M, Powell-Golay K, Baumann P, **Eap CB**. Cytochrome P4503A4 metabolic activity, methadone blood concentrations and methadone doses. *Drug and Alcohol Dependence* 69(2); 205-211, 2003. **Facteur d'impact 2.9 (2003).**
- 160) Allorge D, Chevalier D, Lo-Guidice JM, Mrowinski M, Suard F, Baumann P, **Eap CB**, Broly F. Identification of a novel splice-site mutation in the CYP1A2 gene. *Br J Clin Pharmacol* 56(3); 341-344, 2003. **Facteur d'impact 2.5 (2003).**
- 161) **Eap CB**, Felder C, Uehlinger C, Powell-Golay K. Increase of oral methadone dose in methadone injecting addict patients: a pilot study. *Journal of Addictive Diseases* 22(3): 7 – 17, 2003. **Facteur d'impact 1.7 (2003).**
- 162) Frieboes RM, Sonntag A, Yassouridis A, **Eap CB**, Baumann P, Holsboer F, Steiger A. Clinical outcome after trimipramine in patients with delusional depression – a pilot study. *Pharmacopsychiatry* 36(1) 12 –17, 2003. **Facteur d'impact 2.8 (2003).**
- 163) Le Bloc'h Y, Woggon B, Weissenrieder H, Zullino D, Brawand-Amey M, Spagnoli J, **Eap CB**, Baumann P. Routine therapeutic drug monitoring in patients treated with 10 – 360 mg/day citalopram. *Therapeutic Drug Monitoring*, 25(5): 600-608, 2003. **Facteur d'impact 2.4 (2003).**
- 164) **Eap CB**, Lessard E, Brawand-Amey M, Baumann P, Yessine MA, O'Hara G, Turgeon J. Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. *Pharmacogenetics*, 13(1): 39-47, 2003. **Facteur d'impact 5.9 (2003).**
- 165) Melichar JK, Myles JS, **Eap CB**, Nutt DJ. Using saccadic eye movements as objective measures of tolerance in methadone dependent individuals during the hydromorphone challenge test. *Addiction Biology*, 8(1) 59-66, 2003. **Facteur d'impact 1.3 (2003).**
- 166) Bègré S, von Bardeleben U, Ladewig D, Rochat S, Savary L, Powell K, Baumann P, **Eap CB**. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. *J Clin Psychopharmacol* 22(2) 211-215, 2002. **Facteur d'impact 4.2 (2002).**
- 167) Steinacher L, Vandel P, Zullino DF, **Eap CB**, Brawand-Amey M, Baumann P. Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetics and clinical pilot study. *European Neuropsychopharmacology* 12(3) 255-260, 2002. **Facteur d'impact 2.5 (2002).**
- 168) Fellay J, Marzolini C, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Meaden ER, Pantaleo G, Retelska D, Ruiz L, Schinkel AH, Vernazza P, **Eap CB**, Telenti A. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. *The Lancet* 359(9600) 30 – 36, 2002. **Facteur d'impact 15.4 (2002).**

- 169) Wikell C, **Eap CB**, Josefsson M, Apelqvist G, Ahlner J, Baumann P, Bengtsson F. Disposition of venlafaxine enantiomers in rats with hepatic encephalopathy after chronic drug treatment. *Chirality* 14(4) 347 - 350, 2002. **Facteur d'impact 1.6 (2002).**
- 170) Bondolfi G, **Eap CB**, Bertschy G, Zullino D, Vermeulen A, Baumann P. The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. *Pharmacopsychiatry* 35(2); 50 – 56, 2002. **Facteur d'impact 1.8 (2002).**
- 171) **Eap CB**, Bondolfi G, Zullino D, Bryois C, Fuciec M, Savary-Cosendai L, Jonzier-Perey M, Baumann P. Pharmacokinetic drug interaction potential of risperidone with cytochrome P450 isozymes as assessed by the dextromethorphan, the caffeine and the mephenytoin test. *Ther Drug Monitor* 23(3) 228-231, 2001. **Facteur d'impact 2.0 (2001).**
- 172) **Eap CB**, Bondolfi G, Zullino D, Savary-Cosendai L, Powell-Golay K, Kosel M, Baumann P. Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple dose of fluoxetine in cytochrome P450D6 poor and extensive metabolizers. *J Clin Psychopharmacol* 21(3) 330-334, 2001. **Facteur d'impact 4.0 (2001).**
- 173) Bart PA, Rizzardi GP, Gallant S, Python C, Pantaleo G, **Eap CB**. Methadone blood concentrations are decreased by the administration of abacavir and amprenavir. *Ther Drug Monitor* 23(5); 553-555, 2001. **Facteur d'impact 2.0 (2001).**
- 174) **Eap CB**, Broly F, Mino A, Hämmig R, Déglon JJ, Uehlinger C, Meili D, Chevalley AF, Bertschy G, Zullino D, Kosel M, Preisig M, Baumann P. Cytochrome P-450D6 genotype and methadone steady-state concentrations. *J Clin Psychopharmacol* 21(2) ; 229-234, 2001. **Facteur d'impact 4.0 (2001).**
- 175) **Eap CB**, Bourquin M, Martin JL, Spagnoli J, Livoti S, Powell K, Baumann P, Déglon JJ. Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. *Drug and Alcohol Dependence* 61(1) ; 47-54 2000
- 176) Voirol P, Jonzier-Perey M, Porchet F, Reymond MJ, Janzer RC, Bouras C, Strobel HW, Kosel M, **Eap CB**, Baumann P. Cytochromes P-450 activities in human and rat brain microsomes. *Brain Research* 855(2); 235-243, 2000.
- 177) Bondolfi G, Lissner C, Kosel M, **Eap CB**, Baumann P. Fluoxetine augmentation in citalopram nonresponders: pharmacokinetic and clinical consequences. *Int J Neuropsychopharmacol* 3(1)55-60, 2000.
- 178) **Eap CB**, Bender S, Fischer W, Haarmann C, Powell K, Jonzier Perey M, Cochard N, Berger M, Gastpar M, Baumann P. Steady-state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients. *Therapeutic Drug Monitoring* 22(2) :209-214, 2000.
- 179) **Eap CB**, Yasui N, Kaneko S, Baumann P, Powell K, Otani K. Effects of carbamazepine coadministration on plasma concentrations of the enantiomers of mianserin and of its metabolites. *Therapeutic Drug Monitoring* 21:166-170,1999.
- 180) Felder C, Uehlinger C, Baumann P, Powell K, **Eap CB**. Oral and intravenous methadone use: some clinical and pharmacokinetic aspects. *Drug and Alcohol Dependence* 55:137-143, 1999
- 181) Fjordside L, Jeppesen U, **Eap CB**, Powell K, Baumann P, BrØsen K. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. *Pharmacogenetics* 9:55-60, 1999.
- 182) Kosel M, **Eap CB**, Amey M, Baumann P. Analysis of the enantiomers of citalopram and its demethylated metabolites using chiral liquid chromatography. *J of Chromatogr. Biomed Appl.* 719:234-238, 1998.
- 183) **Eap CB**, Schnyder C, Besson J, Savary L, Buclin T. Inhibition of CYP2E1 by chlormethiazole as measured by chlorzoxazone pharmacokinetics in patients with alcoholism and in healthy volunteers. *Clin. Pharmacol. Ther.* 64:52-57,1998.
- 184) **Eap CB**, Bouchoux G, Cochard N, Savary L, Baumann P. Simultaneous determination of plasma levels of citalopram, paroxetine, sertraline, and their metabolites by gas chromatography-mass spectrometry. *J Chromatogr Sci* 36:365-371, 1998.
- 185) Bondolfi G, Dufour H, Patris M, May JP, Billeter U, **Eap CB**, Baumann P. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. *Am J Psychiatry* 155:499-504, 1998.
- 186) **Eap CB**, Schnyder C, Buclin T, Savary L. Determination of chlorzoxazone and 6-hydroxychlorzoxazone in plasma by gas-chromatography-mass spectrometry. *J. Chromatogr. Biomed. Appl.* 705:139-144, 1998.
- 187) **Eap CB**, de Mendonça Lima C, Macchiardi B, Woggon B, Powell K, Baumann P. Steady-state concentrations of the enantiomers of mianserin and desmethyl mianserin in poor and homozygous and heterozygous extensive metabolizers of debrisoquine. *Ther. Drug Monitor.* 20:7-13, 1998.

- 188) **Eap CB**, Powell K, Baumann P. Determination of the enantiomers of mianserin and metabolites in plasma by capillary electrophoresis after liquid-liquid extraction and on-column sample preconcentration. *J Chromatogr Sci* 35:315-320, 1997.
- 189) **Eap CB**, Bertschy G, Powell K, Baumann P. Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. *J Clin Psychopharmacol* 17: 113-117, 1997.
- 190) **Eap CB**, Gaillard N, Powell K, Baumann P. Simultaneous determination of plasma levels of fluvoxamine and of the enantiomers of fluoxetine and norfluoxetine by gas chromatography-mass spectrometry *J. Chromatogr. Biomed. Appl.* 682: 265-272, 1996.
- 191) **Eap CB**, Finkbeiner T, Gaspar M, Scherbaum N, Powell K, Baumann P. Replacement of (R)-methadone by a double dose of (R,S)-methadone in addicts: interindividual variability of the (R)/(S) ratios and evidence of adaptive changes in methadone pharmacokinetics. *Eur J Clin Pharmacol.* 50:385-389, 1996.
- 192) Bertschy G, **Eap CB**, Powell K, Baumann P. Fluoxetine addition to methadone in addicts-Pharmacokinetic aspects. *Ther. Drug. Monitor.* 18(5):570-572, 1996.
- 193) **Eap CB**, Guentert TW, Schäublin-Loidl M, Stabl M, Koeb L, Powell K, Baumann P. Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin patients. *Clin. Pharmacol. Ther.* 59:322-331, 1996.
- 194) Hervé F, Millot MC, **Eap CB**, Duché JC and Tillement JP. A two-step chromatographic purification of human plasma α 1-acid glycoprotein. Its application to the purification of rare phenotype samples of the protein and their study by chromatography on immobilized metal chelate affinity adsorbent. *J. Chromatogr. Biomed. Appl.* 678:1-14, 1996.
- 195) **Eap CB**, Koeb L, Powell K, Baumann P. Determination of the enantiomers of thioridazine, thioridazine 2-sulfone, and of the isomeric pairs of thioridazine 2-sulfoxide and thioridazine 5-sulfoxide in human plasma. *J. Chromatogr. Biomed. Appl.* 669:271-279, 1995.
- 196) **Eap CB**, Powell K, Campus Souche D, Monney C, Baettig D, Taeschner W, Baumann P. Determination of the enantiomers of mianserin, desmethylmianserin, and 8- hydroxymianserin in the plasma and urine of mianserin-treated patients. *Chirality* 6:555-563, 1994.
- 197) Seifritz E, Holsboer-Trachsler E, Hemmeter U, **Eap CB**, and Baumann P. Increased trimipramine plasma levels during fluvoxamine comedication. *Eur. Neuropsychopharmacol.* 4: 15-20, 1994.
- 198) **Eap CB**, Koeb L, and Baumann P. Determination of trimipramine and its demethylated and hydroxylated metabolites in plasma by gas chromatography-mass spectrometry. *J. Chromatogr. Biomed. Appl.* 652: 97-103, 1994.
- 199) Bertschy G, Baumann P, **Eap CB** and Baettig D. Probable metabolic interaction between methadone and fluvoxamine in addict patients. *Ther. Drug. Monit.* 16: 42-45, 1994.
- 200) Yuasa I, Weidinger S, Umetsu K, Suenaga K, Ishimoto G, **Eap CB**, Duché JC, and Baumann P. Orosomucoid System: 17 additional orosomucoid variants and proposal for a new nomenclature. *Vox Sang* 64: 47-55, 1993.
- 201) Reymond P, Amey M, Souche A, Lambert S, Konrat H, **Eap CB**, and Baumann P. Determination of plasma levels of citalopram and its demethylated and deaminated metabolites by gas chromatography and gas chromatography-mass spectrometry. *J. Chromatogr. Biomed. Appl.* 616: 221-228, 1993.
- 202) **Eap CB**, Koeb L, and Baumann P. Artifacts in the analysis of thioridazine and other neuroleptics. *J. Pharm. Biomed. Anal.* 11: 451-457, 1993.
- 203) **Eap CB**, Koeb L, Holsboer-Trachsler E, and Baumann P. Plasma levels of trimipramine and metabolites in four patients: determination of the enantiomer concentrations of the hydroxy metabolites. *Ther. Drug. Monit.* 14: 380-385, 1992.
- 204) **Eap CB**, Laurian S, Souche A, Koeb L, Reymond P, Buclin T, and Baumann P. Influence of quinidine on the pharmacokinetics of trimipramine and on its effect on the waking EEG of healthy volunteers - A pilot study on two subjects. *Neuropsychobiology* 25: 214-220, 1992.
- 205) Van Dijk W, Pos O, Van der Stelt M, Moshage EHJ, Yap S H, Dente L, Baumann P, and **Eap CB**. Inflammation-induced changes in expression and glycosylation of genetic variants of alpha1-acid glycoprotein. Studies with human sera, primary cultures of human hepatocytes and transgenic mice. *Biochem. J.* 276: 343-347, 1991.
- 206) **Eap CB**, Souche A, Koeb L, and Baumann P. Light-induced racemization: artifacts in the analysis of the diastereoisomeric pairs of thioridazine 5-sulfoxide in the plasma and urine of patients treated with thioridazine. *Ther. Drug. Monit.* 13: 356-362, 1991.
- 207) **Eap CB**, Fischer JF, and Baumann P. Variations in relative concentrations of variants of human alpha1-acid glycoprotein after acute-phase conditions. *Clinica Chimica Acta* 203: 379-386, 1991.

- 208) **Eap CB**, Cuendet C, and Baumann P. Binding of d-methadone, l-methadone, and dl-methadone to proteins in plasma of healthy volunteers: role of the variants of alpha1-acid glycoprotein. *Clin. Pharmacol. Ther.* 47: 338-346, 1990.
- 209) Tomei L, **Eap CB**, Baumann P, and Dente L. Use of transgenic mice for the characterization of human alpha1-acid glycoprotein (orosomucoid) variants. *Hum. Genet.* 84: 89-91, 1989.
- 210) **Eap CB**, Cuendet C, and Baumann P. Binding of amitriptyline to alpha1- acid glycoprotein and its variants. *J. Pharm. Pharmacol.* 40: 767-770, 1988.
- 211) **Eap C B** and Baumann P. Isoelectric focusing of alpha1-acid glycoprotein (orosomucoid) in immobilized pH-gradients with 8 M urea: detection of its desialylated variants using an alkaline phosphatase-linked secondary antibody system. *Electrophoresis* 9: 650-654, 1988.
- 212) **Eap CB**, Cuendet C, and Baumann P. Orosomucoid (alpha1-acid glycoprotein) phenotyping by use of immobilized pH gradients with 8 M urea and immunoblotting. *Hum. Genet.* 80: 183-185, 1988.
- 213) **Eap CB**, Cuendet C, and Baumann P. Selectivity in the binding of psychotropic drugs to the variants of alpha1-acid glycoprotein. *Naunyn-Schmiedeberg's Arch. Pharmacol.* 337: 220-224, 1988.

Other papers (letters, responses, case studies, comments, reviews) published in peer reviewed journals

1. Guinchat V, Ansermot N, Ing Lorenzini K, Politis D, Daali Y, **Eap CB**, Crettol S. Case Report: Opioid use disorder associated with low/moderate dose of loperamide in an intellectual disability patient with CYP3A and P-glycoprotein reduced activity. *Frontiers in Psychiatry* 23 June 2022; <https://doi.org/10.3389/fpsyt.2022.910684>
2. De Leon J, Schoretsanitis G, Smith RL, Molden E, Solismaa A, Seppälä N, Miloslav Kopeček M, Švancer P, Olmos I, Ricciardi C, Iglesias-Garcia C, Iglesias-Alonso A, Spina E, Ruan C-J, Wang C-Y, Tang Y-L, Lin S-K, Kim YS, Kim SH, Rajkumar AP, González-Esquivel DF, Jung-Cook H, Baptista T, Rohde C, Nielsen J, Verdoux H, Quiles C, Sanz EJ, de las Cuevas C, Cohen D, Schulte PFJ, Ertuğrul A, Anıl Yağcıoğlu AE, Chopra N, McCollum B, Shelton C, Cotes RO, Kaithi AR, Kane JM., Farooq S, Ng CH, Bilbily J, Hiemke C, López-Jaramillo C, McGrane I, Lana F, **Eap CB**, Arrojo-Romero M, Rădulescu FS, Seifritz E, Every-Palmer S, Bousman CA, Bebawi E, Bhattachary R, Kelly DL, Otsuka Y, Lazary J, Torres R, Yecora A, Motuca M, Chan SKW, Zolezzi M, Ouanes S, de Berardis D, Grover S, Procyshyn RM, Adebayo RA, Kirilochev OO, Soloviev A, Fountoulakis KN, Wilkowska A, Cubała, WJ, Ayub M, Silva A, Bonelli RM, Villagrán-Moreno JM, Crespo-Facorro B, Temmingh H, Decloedt E, Pedro MR, Takeuchi H, Tsukahara M, Gründer G, Sagud M, Celofiga A, Ignjatovic Ristic D, Bertolucci Ortiz B, Elkis H, Pacheco Palha AJ, Llerena A, Siskind D, Weizman A, Masmoudi R, Leung JG, Buckley PF, Marder SR, Citrome L, Freudenreich O, Correll CU, Müller DJ. An International Adult Guideline for Making Clozapine Titration Safer Worldwide by Using 6 Ancestry-Based Personalized Dosing Titrations, C-Reactive Protein and, When Possible, Clozapine Levels. *Pharmacopsychiatry* Published online: 2021-12-15
3. Kuzin M, Xepapadakos F, Scharrer I, Augsburg M, **Eap CB**, Schoretsanitis G. The role of cytochrome P450 enzyme genetic variants in cannabis hyperemesis syndrome – A case report. *Basic & Clinical Pharmacology & Toxicology* 2021;129:82-85
4. **Eap CB***, Gründer G*, Baumann P, Ansermot N, Conca A, Corruble E, Crettol S, Dahl ML, de Leon J, Greiner C, Howes O, Kim E, Lanzenberger R, Meyer JH, Moessner R, Mulder H, Müller DJ, Reis M, Riederer P, Ruhe HG, Spigset O, Spina E, Stegman B, Steimer W, Stingl J, Suzen S, Uchida H, Unterecker S, Vandenberghe F, Hiemke C. Tools for optimizing pharmacotherapy in psychiatry (Therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): Focus on antidepressants. *World J Biol Psychiatry* 2021 oct; 22(8):561-628. * Joint first authorship.
5. Vandenberghe F, Gilet P, Daali Y, Favre L, **Eap CB**. Bioavailability of vortioxetine after a Roux-en-Y gastric bypass (letter). *Obesity Surgery* Mar;(2021) 31:1353-1356
6. Schoretsanitis G, de Leon J, **Eap CB**, Kane JM, Paulzen M. Clinically significant drug-drug interactions with agents for attention-deficit/hyperactivity disorder. *CNS Drugs.* 2019 Dec;33(12):1201-1222. **Facteur d'impact 4.2 (2018)**
7. Fischer Fumeaux CJ, Morisod Harari M, Weisskopf E, **Eap CB**, Epiney M, Vial Y, Csajka C, Bickle Graz M, Panchaud A. Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence – an update (review). *Expert opinion on Drug Safety* 2019;18(10):949-963. **Facteur d'impact 3.2 (2018).**
8. **Eap CB**. Personalized prescribing : a new medical model for clinical implementation of psychotropic drugs (review). *Dialogues in Clinical Neurosciences*, 18 (No 3), 313-322, 2016. **Facteur d'impact 4.0 (2016).**

9. Chen F, Richard S, D'Andrea G, Grandjean C, **Eap CB**. Accidentally detected asymptomatic Wolff-Parkinson-White syndrome in an adolescent with depression (case report). *Swiss Archives of Neurology, Psychiatry and Psychotherapy* 2016;167(3):94-96. **Facteur d'impact 2.9 (2016)**.
10. Paulzen M, **Eap CB**, Gründer G, Kuzin M. Pharmacokinetic Interaction between Valproic acid, Meropenem and Risperidone (case report). *J Clin Psychopharmacol* 2016 Feb; 36(1):90-2. **Facteur d'impact 2.3 (2016)**.
11. Liakoni E, Huber X, Crettol S, **Eap CB**, Liechti ME. Eine unerwünschte Wirkung von Methadon und Moxifloxacin (case report). *Swiss Medical Forum* 16(7):176-177, 2016
12. Ansermot N, Chocron O, Herrera F, **Eap CB**. Severe manic episode associated with tramadol in a patient with recurrent depressive disorder (Case report). *J Clin Psychopharmacol* 2015; 35(2):203-4. **Facteur d'impact 3.0 (2015)**.
13. Weisskopf E, Fischer Fumeaux C, Bickle Graz M, Moriso Harari M, Tolsa JF, Vial Y, **Eap CB**, Csajka C, Panchaud A. Risk-benefit balance assessment of SSRI antidepressants use during pregnancy and lactation based on best available evidence (review). *Expert Opinion on drug safety* (2015) 14(3) :413-427. **Facteur d'impact 2.9 (2015)**.
14. Guessous I, **CB Eap**, Bochud M. Blood pressure in relation to coffee and caffeine consumption (review). *Current Hypertension Rep* 2014; 16:468. **Facteur d'impact 3.4 (2014)**.
15. Panchaud A, Weisskopf E, Winterfedl U, Baud D, **Eap CB**, Csajka C, Widmer N. Médicaments et grossesse: modifications pharmacocinétiques liées à la grossesse et place du suivi thérapeutique pharmacologique (revue) *Thérapie* 69(3): 223-34 (2014). **Facteur d'impact 0.5 (2014)**.
16. Ansermot N, Hodel PF, **Eap CB**. Serotonin syndrome after adjunction of mirtazapine to escitalopram (case report). *J Clin Psychopharmacol* 2014; 34(4):540-541. **Facteur d'impact 3.2 (2014)**.
17. Paulzen M, Henkel K, Tauber S, Reich A, **Eap CB**, Gründer G. Plasma levels and cerebrospinal fluid penetration of venlafaxine in a patient with a non-fatal overdose during a suicide attempt (case report). *J Clin Psychopharmacol* 2014; 34(3):398-399. **Facteur d'impact 3.2 (2014)**.
18. Crettol S, de Leon J, Hiemke C, **Eap CB**. Pharmacogenomics in psychiatry: from TDM to genomic medicine (review). *Clin Pharmacol Ther* 2014, 95(3):254-257. **Facteur d'impact 7.9 (2014)**.
19. Noetzli M, **Eap CB**. Pharmacodynamic, pharmacokinetic and pharmacogenetics aspects of drugs used in the treatment of Alzheimer's disease (review). *Clin Pharmacokinetics* 2013, 52:225-241. **Facteur d'impact 5.5 (2013)**.
20. Chanachev A, Conus P, **EAP CB**. Addition of aripiprazole to the clozapine may be useful in reducing anxiety in treatment resistant-schizophrenia (case report). *Case report in Psychiatry*, volume 2011, article ID 846489, doi:10.1155/2011/846489
21. Ansermot N, Albayrak Ö, Schläpfer J, Crettol S, Croquette-Krokar M, Bourquin M, Faouzi M, Rey F, Scherbaum N, **Eap CB**. Letter « Does methadone prolong QTc interval by depleting testosterone levels? In Reply" *Arch Int Med* 170(15)1408, 2010. **Facteur d'impact 10.6 (2010)**.
22. Choong E, Dobrinas M, Carrupt PA, **Eap CB**. The permeability glycoprotein: a focus on enantioselectivity and brain distribution (review). *Expert Opinion on drug metabolism and toxicology* 6(8), 953-965, 2010. **Facteur d'impact 3.4 (2010)**.
23. Oneda B, Preisig M, Dobrinas M, **Eap CB**. Lack of associations between genetic polymorphisms of ARRB2 and alcohol dependence in a Caucasian population. (letter) *Alcohol and alcoholism* 45(6): 590-591, 2010. **Facteur d'impact 2.6 (2010)**.
24. Bochud M, Bovet P, Burnier M, **Eap CB**. CYP3A5 and ABCB1 genes and hypertension (review) *Pharmacogenomics* 10(3), 477-87, 2009. **Facteur d'impact 3.9 (2009)**.
25. Bochud M, **Eap CB**, Bovet P, Burnier M. La génétique de l'hypertension : rôle des gènes CYP3A5 et ABCB1 dans le contrôle de la tension artérielle (review). *Médecine cardiovasculaire / Kardiovaskuläre Medizin* 11(11) :353-60, 2008
26. Crettol S, Schläpfer J, Abriel H, **Eap CB**. Response to "Methadone induced QTc prolongation. Is it due to stereoselective block of hERG or to inappropriate QT interval correction?" (Letter) *Clin Pharmacol Ther* 83(5) 672, 2008. **Facteur d'impact 7.6 (2008)**.
27. Crettol S, Déglon JJ, Besson J, Croquette-Krokar M, Hämmig R, Gothuey I, Monnat M, **Eap CB**. No influence of ABCB1 haplotype on methadone dosage requirement (Letter). *Clin Pharmacol Ther* 83(5) 668-669, 2008. **Facteur d'impact 7.6 (2008)**.
28. Dobrinas M and **Eap CB**. Cytochrome P4503A pharmacogenetics (review). *HIV-pharmacogenetics.org HIV PGX* 2:2, 2007.
29. Crettol S, Monnat M, **Eap CB**. Could pharmacogenetic data explain part of the interindividual sensitivity to methadone-induced respiratory depression? (Commentary). *Critical Care* 11:119, 2007. **Facteur d'impact 3.8 (2007)**.

30. Crettol S and **Eap CB**. Pharmacokinetic and pharmacogenetic factors influencing methadone plasma levels. (Review). *Heroin addiction and related clinical problems* 9(2):39-46, 2007.
31. Baumann P, Barbe R, Vabre-Bogdalova A, Garran E, Crettol S, **Eap CB**. Epileptiform seizure following sertraline treatment in an adolescent suffering from obsessive compulsive disorder with CYP2B6 and CYP2D6 genetic deficiency (Letter). *J Clin Psychopharmacol* 26(6):679-681, 2006. **Facteur d'impact 4.6 (2006)**.
32. Jaquenoud-Sirot E, Willem van der Velden J, Rentsch K, **Eap CB**, Baumann P. Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance (Review). *Drug safety*, 29(9) 735-68, 2006. **Facteur d'impact 3.7 (2006)**.
33. Holzer L, **Eap CB**. Aripiprazole and suicidality: a case report (letter). *Int Clin Psychopharmacol* 21(2) 125-126, 2006. **Facteur d'impact 3.1 (2006)**.
34. Stephan PL, Jaquenoud Sirot E, Mueller B, **Eap CB**, Baumann P. Adverse drug reactions following nonresponse in a depressed patient with CYP2D6 deficiency and low CYP3A4/5 activity: a pharmacovigilance case report (letter). *Pharmacopsychiatry* 39(4) 150-2, 2006. **Facteur d'impact 2.8 (2006)**.
35. Albrecht A, Morena P, Baumann P, **Eap CB**. High dose of depot risperidone in a non-responder schizophrenic patient (Letter). *J Clin Psychopharmacol* 24(6):673-4, 2004. **Facteur d'impact 4.4 (2004)**.
36. **Eap CB**, Jaquenoud Sirot E, Baumann P. Therapeutic monitoring of antidepressants in the era of pharmacogenetics studies (Review). *Ther Drug Monitor* 26 (2), 152-155 (2004). **Facteur d'impact 2.8 (2004)**.
37. Jaquenoud Sirot E, **Eap CB**, Baumann P. Bedeutung von TDM und Pharmakogenetik bei Untersuchungen über Arzneimittelsicherheit in der Psychiatrie (Review). *Psychopharmakotherapie* 10: 5-10, 2003. **Facteur d'impact 0.7 (2003)**.
38. Eich-Höchli D, Oppliger R, Powell-Golay K, Baumann P, **Eap CB**. Methadone maintenance treatment and St John's wort (Letter). *Pharmacopsychiatry*, 36: 35-37, 2003. **Facteur d'impact 2.8 (2003)**.
39. Baumann P, Zullino DF, **Eap CB**. Enantiomer's potential in psychopharmacology - A critical analysis with special emphasis on the antidepressant escitalopram (Review). *European Neuro Psychopharmacology* 12(5) 433 – 444, 2002. **Facteur d'impact 2.5 (2002)**.
40. Hilleret H, Voirol P, Bovier P, Giannakopoulos P, Zullino D, Baumann P, Giroud C, Rivier L, **Eap CB**. Very long half-life of paroxetine following intoxication in an extensive cytochrome P4502D6 metabolizer: a case report (Case report). *Ther Drug Monitor*, 24(4) 567-569, 2002. **Facteur d'impact 2.1 (2002)**.
41. Fellay J, Back D, Schinkel AH, **Eap CB**, Telenti A. Multidrug resistance and response to antiretroviral treatment (Correspondence). *The Lancet*, 359: 2114-2115, 2002. **Facteur d'impact 15.4 (2002)**.
42. Zullino DF, Delessert D, **Eap CB**, Preisig M, Baumann P. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine and olanzapine (Case report). *Int. Clin Psychopharmacol*, 17(3) 141-143, 2002. **Facteur d'impact 2.8 (2002)**.
43. **Eap CB**, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence (Review). *Clinical Pharmacokinetics* 41:1153-1193, 2002. **Facteur d'impact 4.2 (2002)**.
44. Baumann P, **Eap CB**, Zullino D. Fluvoxamine and perphenazine for psychosis in alzheimer's disease: pharmacokinetic considerations (Letter). *The Journal of nervous and mental disease*, 189(11) 798-799, 2001. **Facteur d'impact 1.5 (2001)**.
45. Zullino D, **Eap CB**, Voirol P. Ondansetron in the treatment of tardive dyskinesia (Letter). *Am J Psy* 158(4) 657-658, 2001. **Facteur d'impact 6.9 (2001)**.
46. Baumann P, **Eap CB**. Enantiomeric antidepressant drugs should be considered on individual merit (Review). *Hum Psychopharmacol Clin Exp* 16(S2) S85-S92, 2001. **Facteur d'impact 1.0 (2001)**.
47. **Eap CB**, Bertel-Laubscher R, Amey M, Baumann P. Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: a case report (Case report). *Pharmacopsychiatry* 33(3) 112-115, 2000.
48. **Eap CB**. Opiate withdrawal symptoms induced by antiretroviral drugs in patients receiving methadone (Letter). *Annals of Pharmacotherapy* 34(9) ; 1077-1078, 2000.
49. Leavitt SB, Shindermann M, Maxwell S, **Eap CB**, Paris P. When « enough » is not enough: New perspectives on optimal methadone maintenance dose (Review). *Mount Sinai Journal of Medicine* 67(5-6): 404-411, 2000.
50. Marzolini C, Troillet N, Telenti A, Baumann P, Decosterd LA, **Eap CB**. Efavirenz decreases methadone blood concentrations (Letter). *AIDS* 14(9) : 1291-1292, 2000.

51. Voirol P, **Eap CB**, Baumann P. Monitoring thérapeutique des psychotropes et tests pharmacogénétiques en psychiatrie (Review). *Revue Médicale de la Suisse Romande* 120(2) ; 99-104, 2000.
52. **Eap CB**. On the usefulness of therapeutic drug monitoring of methadone (Letter). *European Addiction Research* 6(1) :31-33, 2000
53. **Eap CB**, Déglon JJ, Baumann P. Pharmacokinetics and pharmacogenetics of methadone: clinical relevance (Review). *Heroin addiction and related clinical problems* 1:19-34, 1999
54. Baumann P, Broly F, Markus K, **Eap CB**. Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2D6 genotyping (Letter). *Pharmacopsychiatry* 31:72, 1998.
55. Bender S. and **Eap CB**. Very high cytochrome P450IA2 activity and non-response to clozapine (Letter). *Archives of General Psychiatry* 55:1048-1050,1998
56. **Eap CB**, Buclin T, Buchwalder PA, Gutmann N, Baumann P. Multiple and simultaneous phenotyping tests: beware of ascorbic acid when determining the mephenytoin (S)/(R) ratio (Letter). *Clinica Chimica Acta* 271:105-107, 1998
57. **Eap CB**, Bertschy G, Finkbeiner T, Gastpar M, Scherbaum N, Baumann P. High interindividual variability of methadone enantiomer blood levels to dose ratios (Letter). *Archives of General Psychiatry* 55:89-90, 1998.
58. Bondolfi G, Rubin C, Bryois C, **Eap CB**. Galactorrhea induced by a pharmacodynamic interaction between citalopram, alprazolam and tramadol: a case report (Letter). *Thérapie* 352:76-77 1997
59. **Eap CB**, Baumann P. Analytical methods for the quantitative determination of selective serotonin reuptake inhibitors for therapeutic drug monitoring purposes in patients (Review). *J. Chromatogr. Biomed. Appl.* 686: 51-63, 1996.
60. Conus P, Bondolfi G, **Eap CB**, Macciardi F, Baumann P. Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient (Case report). *Pharmacopsychiatry* 29:108-110, 1996.
61. Baumann P, Hatzinger M, U. Hemmeter, E. Seifritz, **Eap CB**, Holsboer E. Influence of amesergide treatment on the dextromethorphan test (Letter). *Br J Clin Pharmacol* 38:151-152, 1994.

c. Other papers published for didactic purposes in journals without peer review

1. Grandjean C, Vandenberghe F, Dubath C, Sibailly G, Ansermot N, Crettol S, Eap CB. Prescription d'antipsychotiques chez les adultes : A quoi faut-il être attentif ? *Revue Médicale Suisse* 2023 ; 19 : 107-12
2. Conus P, Hyde E, Mazallon R, **Eap CB**. Psychiatrie - Impact métabolique défavorable des psychotropes : un diagnostic précoce possible et nécessaire *Revue médicale Suisse* 2022 ; 18 :198-200
3. Grandjean C, Crettol Wavre S, Kaazal Y, JS Zozaya, Ansermot N, Vandenberghe F, Guibet S, **Eap CB**. Gabapentinoïdes : mésusages et addictions. *Rev Med Suisse*. 2021 Dec 15;17:2206-8.
4. Grandjean C, Crettol Wavre S, Kaazal Y, JS Zozaya, Ansermot N, Vandenberghe F, Guibet S, **Eap CB**. Recommandations de prise en charge des mésusages et addictions aux benzodiazépines *Rev Med Suisse*. 2021 ; Oct 13 ;17(754):1754-9
5. Grandjean C, Crettol Wavre S, Ansermot N, Vandenberghe F, Guibet S, **Eap CB**. Traitement de l'insomnie, par quoi commencer ? *Rev Med Suisse*. 2021 May 5;17(737):890-897.
6. Crettol Wavre S, Ansermot N, Sibailly G, Vandenberghe F, Grandjean C, Robalo BT, Fassassi Gallo S, Thonney J, Solida-Tozzi A, Conus P, **Eap CB**. Agitation aiguë chez l'adulte : proposition d'un algorithme de traitement psychopharmacologique. *Rev Med Suisse* 2020; 16 :1751-5
7. **Eap CB**. Les antidépresseurs sont-ils efficaces ? : Oui. *Psychoscope* 2018. Page 34
8. Weisskopf E, Fumeaux CF, Bickle Graz M, Harari MM, Epiney M, Tolsa CB, Rouiller S, Tolsa J-F, Vial Y, **Eap CB**, Csajka C, Panchaud A. Le bon usage des antidépresseurs ISRS durant la grossesse- le défi de l'évaluation de la balance bénéfico-risque. *Revue médicale Suisse* 2016 Mar 16 ;12(510):561-6
9. Conus P, Herrera F, Berney S, Gaillard B, Beretta V, Vandenberghe F, **Eap CB**. New developments in psychiatry. *Revue Médicale Suisse* 2016; 13 Jan, 12(500) :86-9
10. Crettol S & **Eap CB**. Cytochrom-P450-Genotypisierung: ein Instrument zur Personalisierung der medikamentösen Behandlung in der Psychiatrie. *Pipette* 2013; N°6: Theme 10-11

11. Panchaud A, Csajka C, Weisskopf E, Vial Y, Lepigeon K, Tolsa JF, Bickel – Graz M, Fischer C, **Eap CB**, Moriso Harari M. Etude multicentrique: "antidépresseurs, grossesse et allaitement". Forum (Société Suisse de Gynécologie et d'Obstétrique 2/13, pages 03-06, 2013.
12. Crettol S, **Eap CB**. Cytochromes P450: génotypes et/ou phénotypes pour l'individualisation du traitement médicamenteux. Pipette, 1, Février 2013, pp 10-11
13. Conus P, Despland J-N, Herrera F, Chanachev A, **Eap CB**, Mall JF, Ebbing K, von Gunten A. Psychiatrie. Revue Médicale Suisse 9 Janvier 2013, p 76-79.
14. Rentsch K, Buhl D, **Eap CB**, Fathi M, Thormann W, Werner D. Monographs on drugs which are frequently analyzed in therapeutic drug monitoring (review). J Lab med 36(2):77-88, 2012.
15. Guex P, Conus P, Pomini V, Kramer U, Bonsack C, **Eap CB**. Nouveautés en médecine 2010 – Psychiatrie. Revue Médicale Suisse 278 (7) : 150-153, 2011
16. Chanachev A, Conus P, **EAP CB**. La pharmacogénétique / pharmacogénomique en psychiatrie : perspectives théoriques et perspectives pour l'avenir. L'Information Psychiatrique 87(9) :697-703, 2011
17. Solida A, Choong E, Lechaire C, **Eap CB**, Conus P. Syndrome métabolique et antipsychotiques atypiques : recommandations et prise en charge clinique. L'Information Psychiatrique 87(9) :715-724, 2011
18. Rentsch K, Buhl D, **Eap CB**, Fathi M, Thormann W, Werner D. Monographs on drugs which are frequently analyzed in therapeutic drug monitoring (review). J Lab med 35 (2):81-91, 2011.
19. Rossier MF, Rebsamen M, Crettol S, **Eap CB**, Rentsch K. Evidence based medicine for pharmacogenetics. Pipette (4). Aout 2010, Thème 13
20. Rentsch K, Buhl D, **Eap CB**, Fathi M, Jöchle W, Magnin JL, Thormann W, Werner D. Monographs on drugs which are frequently analyzed in therapeutic drug monitoring (review). J Lab med 34 (3):129-39, 2010.
21. Rentsch K, **Eap CB**, Fathi M, Grignaschi N, Magnin JL, Thormann W, Todesco L, Werner D. Monographs on drugs which are frequently analyzed in therapeutic drug monitoring (review). J Lab med 33(2):99-120, 2009
22. Dobrinas M, Cornuz J, Kohler Serra M, Puhl M, **Eap CB**. Aspects génétiques de la consommation de tabac et impact sur la prise en charge clinique (review). Revue Médicale Suisse 5: 1463-1467, 2009
23. Rentsch K, **Eap CB**, Fathi M, Grignaschi N, Magnin JL, Thormann W, Todesco L, Werner D. Monographs on drugs which are frequently analyzed in therapeutic drug monitoring (review). J Lab med 32(5):372-81, 2008
24. Besson J, **Eap CB**, Khazaal Y, Montagrin Y, Rihs-Middel M, Simon O, Tissot H, Tomei A, Zumwald C, Zullino D. Nouveautés en médecine 2007: Dépendances. Revue médicale Suisse, 139 : 8 – 13, 2008.
25. Choong E, Solida A, Lechaire C, Conus P, **Eap CB**. Suivi du syndrome métabolique induits par les antipsychotiques atypiques: Recommandations actuelles et perspectives futures basées sur les études pharmacogénétiques. Revue Médicale Suisse 4 :1994-9, 2008
26. **Eap CB**. Méthadone et cardiotoxicité. Rapport annuel de la Fondation Phenix 2008
27. Widmer N, Csajka C, Werner D, Grouzmann E, Decosterd LA, **Eap CB**, Biollaz J, Buclin T. Suivi thérapeutique des médicaments (review, part I) : les principes. Rev Med Suisse 4: 1644-8, 2008.
28. Widmer N, Werner D, Grouzmann E, **Eap CB**, Csajka C, Marchetti O, Fayet A, Csajka C Decosterd LA, Buclin T. Suivi thérapeutique des médicaments: la pratique clinique (review, part II) Rev Med Suisse 4 :1649 - 60, 2008
29. Besson J, **Eap CB**, Rougemont-Buecking A, Simon O, Nikolov C, Bonsack C, Gothuey I. (review) Acquisitions thérapeutiques 2005: Dépendances Revue Médicale Suisse, 2(47) 9-13, 2006
30. **Eap CB**. Apport de la Pharmacogénétique dans la prise en charge médicamenteuse des addictions. THS La Revue des Addictions. Vol VI (no 23), Septembre 2004, p 1173-1175.
31. Jacquenoud Sirot E, **Eap CB**, Baumann P. Die Bedeutung des therapeutischen Drug Monitoring (TDM) und der Pharmacogenetik bei Untersuchungen über Arzneimittelsicherheit in der Psychiatrie. AGNP-TDM Magdeburg 2002
32. De Mendonça Lima CA, **Eap CB**, Baumann P. La psychopharmacothérapie dans le domaine de la psychogériatrie : actualité, problèmes, perspectives (Review). *Revue Médicale de la Suisse Romande* 120 (2);131-136, 2000.
33. **Eap CB**. Nouvelles études psychopharmacologiques sur la méthadone : implications pour le traitement de la dépendance aux opiacés (Review). *Revue Médicale de la Suisse Romande* 120(2) ; 111-116, 2000.

34. **Eap CB**, Déglon JJ, Baumann P. Metadone: farmacocinetica e farmacogenetica. *Italian Journal of the Addictions*, 1999, Mars 22-23, 41-47.
35. Baumann P, **Eap CB**. Mechanismen und klinische Bedeutung von pharmakokinetischen Interaktionen. *Medizinpiegel. Ärztejournal für die Schweiz*, 1999, 6, 25-28
36. **Eap CB**. Résistance à un traitement antidépresseur. Importance et intérêt du monitoring thérapeutique et de la pharmacogénétique. *Compte rendu du XVIIe congrès de l'Association pour la Promotion des Hôpitaux de Jour pour Personnes Agées (APHJPA)*, 5-6 Juin 1997, Prilly-Lausanne.
37. Baumann P. and **Eap CB**. Genetics, biochemistry, physiological functions, and pharmacology of alpha1-acid glycoprotein. *Académie Suisse des Sciences Naturelles XIII*: 32-34, 1989.
38. Baumann P. and **Eap CB**. Rapport du Congrès international: Genetics, biochemistry, physiological functions, and pharmacology of alpha1-acid glycoprotein. *Bulletin de l'Académie Suisse des Sciences Médicales 77-79*, 1989.

Book chapters, editing, monographies

1. **Eap CB**, Sibailly G, Pharmacologie du sujet âgé. Chapitre dans le *Vademecum de Psychiatrie Gériatrique 2020*. Sous la direction de Marie-Thérèse Clerc, Jean-Frédéric Mall, Armin von Gunten. Chapitre 1, pages 155-164. RMS éditions/Médecine et hygiène.
2. Besson M, **Eap CB**, Schaad N. *Vademecum psychiatrie* (in press)
3. Bertholet L, Do KQ, Schenk F, Ansermot N, **Eap CB**. Un regard sur la schizophrénie *Actualités Psychologiques 2009-22* (Introduction à la Neurosciences psychiatrique : appui de cours). pp. 77-106, 2009
4. Giroud C, **Eap CB**, Favrat B, Sporkert F, Augsburg M, Rochat B, Montoya JP, Castella V, Mangin P. Impact of oral cannabis on driving skills and genetic vulnerability to psychotic symptoms. *XV Mosbacher symposium der GTFCh*. April 2007 Mosbach Baden Germany. <http://www.gtfch.org/cms/index.php/proceedings/162-tagungsband-zum-xv-gtfchs-symposium-1821042007-in-mosbach>
5. Crettol S and **Eap CB**. Pharmacogenomics of opioids. In "Pharmacogenomics and proteomics: Enabling the practice of personalized medicine". M Linder, R Valdes, SH Wong (ed). American Association of Clinical Chemistry press, chapter 19, pages 187-198, 2006.
6. **Eap CB**, Déglon JJ, Baumann P. Pharmacokinetics and pharmacogenetics of methadone: clinical relevance. Heroin assisted treatment. Swiss Federal Office of Public Health (Health Sciences). Verlag Hans Huber. Chapter 27, pages 251-265 (2005).
7. **Eap CB**, Baumann P. Apport de la pharmacogénétique dans le traitement médicamenteux des addictions : l'exemple de la méthadone. *Federal Office of Public Health. Recherches de l'OFSP en matière de dépendances 2002-2003, Volume 1/3 : Recherche Fondamentale*, page 65-69, 2005
8. **Eap CB**. Apport de la Pharmacogénétique dans la prise en charge médicamenteuse des addictions. *Acte du colloque THS Toxicomanies, Hépatites, Sida. Volume 1 (Addictions et Toxicomanies)*, Editions Frison-Roche (Paris). Pages 103-108 (2004)
9. Uchtenhagen A, Ali R, Berglund M, Brenneisen R, **Eap CB**, Farrell M, Mattick R, McLellan T, Rehm J, Simpson D. Methadone as a medicine for the management of opioid dependence and HIV/AIDS prevention. Geneva, World Health Organisation, 2004
10. **Eap CB**, Baumann P. Pharmacologie clinique et Pharmacogénétique de la méthadone. *Federal Office of Public Health. Recherches de l'OFSP en matière de dépendances 1999-2001. Vol 1/3 Recherche fondamentale*, page 52-56, 2003.
11. **Eap CB**. Variabilité interindividuelle de la réponse thérapeutique aux médicaments de substitution : le cas de la méthadone. *THS La revue des Addictions. Publication trimestrielle de la Société Européenne Toxicomanies, Hépatites, Sida. Actes du colloque THS (Toxicomanies, Hépatites, Sida) 5*. Editions Frison-Roche, Paris, 2002, 149 – 157.
12. Baumann P, Zullino D, **Eap CB**. Pharmakokinetik und therapeutisches Monitoring von Antidepressiva. In: *Depression 2000* (G Laux ed.). Bayer-ZNS-Symposium XVI. Springer Verlag Berlin Heidelberg 2002. Chapter four, 37 – 50.
13. Baumann P, Zullino DF, Jaquenoud Sirot E, Paus E, **Eap CB**. Therapy with antidepressants: pharmacogenetics aspects. In *Advances in Biological Psychiatry (Vol 21) Perspectives in affective disorders*, Wolfgang Kaschka (ed) Karger, Basel, 2002, Vol 21, 95 – 111.
14. Baumann P. and **Eap CB**. Pharmacogenetics of chiral psychotropic drugs. In "Pharmacogenetics of psychotropic drugs" Cambridge University Press. Bernard Lerer (ed). 2002; 181-214.

15. **Eap CB**, Voirol P, Baumann P, de Mendonça Lima C. Prescription des antidépresseurs chez la personne âgée : A propos de quelques spécificités. Collection : L'année gérontologique (Serdit Edition), V. Camus, L Schmitt (rédacteurs). 2001, 131-150.
16. **Eap CB**, Baumann P. Pharmacocinétique et pharmacogénétique de la méthadone. Federal Office of Public Health. Recherches de l'OFSP en matière de dépendances 1996-98, Volume 1 / 4 : Recherche fondamentale, April 2000, 16-19.
17. **Eap CB**, Bertschy G, Baumann P. Pharmacogenetics of methadone. Federal Office of Public Health (in press)
18. Baumann P, **Eap CB**, Steimer W, Kosel M, Voirol P. Ultraschnelle Metabolisierer: Grundlagen and klinische Bedeutung. Psychopharmakotherapie, 1999, vol 2, 62-64
19. Baumann P, **Eap CB**, Voirol P. Clinical pharmacokinetics of SSRIs. In « Selective Serotonin Reuptake inhibitors (SSRIs): Past, present and future. S. Clare Stanford (Ed) R.G. Landes Company, Austin, Texas, USA (Publisher). Page 9 - 27 (1999).
20. Baumann P, **Eap CB**, de Mendonça Lima C, Zullino D. Characteristics of psychotropic drug metabolism in geriatric patients. In « Mental Disorders in the Elderly: New Therapeutic Approaches ». Brunello N, Langer SZ, Racagni G (eds). Int Acad Biomed Drug Res Basel, Karger, 1998, Vol 13, pp 159-170.
21. **Eap CB**, Bertschy G. Méthadone : nouveaux aspects. Office Fédéral de la Santé Publique. Aertzliche Verschreibung von Betäubungsmitteln: Praktische Umsetzung (PROVE-Band II)
22. **Eap CB**, Bertschy G, Baumann P. Analyse de la méthadone dans le plasma. Dans « Recherches de l'OFSP en matière de dépendances ». Office Fédéral de la Santé Publique (1997)
23. **Eap CB** and Baumann P. The alpha1-acid glycoprotein: structure and possible functions in the acute phase response. In: *Acute phase proteins. Molecular biology, biochemistry, and clinical application*, edited by A. Mackiewicz, I. Kushner, and H. Baumann. Boca Raton: CRC Press, 1993, p. 107-116.
24. Baumann P. and **Eap CB**. Klinische Relevanz pharmakogenetischer Phänotypisierungen. In: *Biologische Psychiatrie der Gegenwart. 3. Drei-Länder Symposium für Biologische Psychiatrie, Lausanne, September 1992*, edited by P. Baumann, W. W. Fleischhacker, W. Gaebel, G. Laux, H. J. Möller, B. Saletu, and B. Woggon. Wien, New York: Springer-Verlag, 1993, p. 658-663.
25. **Eap CB**, Souche A, Koeb L, and Baumann P. Light-induced racemization of the diastereoisomeric pairs of thioridazine 5-sulfoxide: origin of artifacts in the TDM of thioridazine. In: *Recent developments in therapeutic drug monitoring and clinical toxicology.*, edited by I. Sunshine. New York: Marcel Dekker, Inc., 1992, p. 111-115.
26. Baumann P and **Eap CB**. Therapeutic drug monitoring: role of alpha1-acid glycoprotein (AGP) binding. In: *Recent developments in therapeutic drug monitoring and clinical toxicology.* edited by I. Sunshine. New York: Marcel Dekker, 1992, p. 153-157.
27. Baumann P. and **Eap CB**. Plasma monitoring of antidepressants: clinical relevance of the pharmacogenetic of metabolism and of alpha1-acid glycoprotein binding. *Biological Psychiatry* 1: 362-364, 1991.
28. **Eap CB** and Baumann P. Pharmacogenetics of drug binding to albumin and alpha1-acid glycoprotein. In: *Plasma binding of drugs and its consequences*, edited by F. Belpaire, M. Bogaert, J. -P. Tillement, and R. Verbeeck. Ghent: Academia Press, 1990, p. 69-82.
29. **Eap CB** and Baumann P. The genetic polymorphism of human alpha1-acid glycoprotein. In: *Alpha1-acid glycoprotein: genetics, biochemistry, physiological functions and pharmacology*, edited by P. Baumann, C. B. Eap, W. E. Müller, and J. -P. Tillement. New York: Alan R. Liss, Inc., 1989, p. 111-125
30. Bree F, **Eap CB**, Baumann P, Duche JC, and Tillement JP. Comparison of drug binding capacities of two AAG peptidic variants of human origin. In: *Alpha1-acid glycoprotein: genetics, biochemistry, physiological functions and pharmacology*, edited by P. Baumann, C. B. Eap, W. E. Müller, and J. -P. Tillement. New York: Alan R. Liss, Inc., 1989, p. 399-403.
31. Baumann P. and **Eap CB**. Das saure alpha1-Glycoprotein: ein Modell zum Studium der Eiweissbindung von psychotropen Pharmaka. In: *Biologische Psychiatrie*, edited by B. Saletu. Stuttgart, New York: Georg Thieme Verlag, 1989, p. 358-361.
32. Baumann P. and **Eap CB**. Contribution of the variants of alpha1-acid glycoprotein to its binding of drugs. In: *Alpha1-acid glycoprotein: genetics, biochemistry, physiological functions, and pharmacology*, edited by P. Baumann, C. B. Eap, W. E. Müller, and J. -P. Tillement. New York: Alan R. Liss, Inc., 1989, p. 379-397.
33. Baumann P, **Eap CB**, Müller WE and Tillement JP. *Alpha1-acid glycoprotein: genetics, biochemistry, physiological functions and pharmacology*. New York: Alan R. Liss, Inc., 1989, p. 1-469.